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A B S T R A C T
Background
Dupuytren’s disease is a benign fibroproliferative disorder that causes the fingers to be drawn into the palm via formation of new tissue
under the glabrous skin of the hand. This disorder causes functional limitations, but it can be treated through a variety of surgical
techniques. As a chronic condition, it tends to recur.
Objectives
To assess the benefits and harms of different surgical procedures for treatment of Dupuytren’s contracture of the index, middle, ring
and little fingers.
Search methods
We initially searched the following databases on 17 September 2012, then re-searched them on 10 March 2014 and on 20 May 2015:
the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library, the British Nursing Index and Archive (BNI),
the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Latin American Caribbean Health Sciences
Literature (LILACS), Ovid MEDLINE, Ovid MEDLINE-In-Process and Other Non-Indexed Citations, ProQuest (ABI/INFORM
Global and Dissertations & Theses), the Institute for Scientific Information (ISI) Web of Science and clinicaltrials.gov. We reviewed
the reference lists of short-listed articles to identify additional suitable studies.
Selection criteria
We included randomised clinical trials and controlled clinical trials in which groups received surgical intervention for Dupuytren’s
disease of the index, middle, ring or little finger versus control, or versus another intervention (surgical or otherwise). We excluded the
thumb, as cords form on the radial aspect of the thumb and thus are not readily accessible in terms of angular deformity. Furthermore,
thumb disease is rare.
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Data collection and analysis
A minimum of two review authors independently reviewed search results to select studies for inclusion by using pre-specified criteria,
assessed risk of bias of included studies and extracted data from included studies.
We grouped outcomes into the following categories: (1) hand function, (2) other patient-reported outcomes (e.g. satisfaction, pain),
(3) early objective outcomes (e.g. correction of angular deformity), (4) late objective outcomes (e.g. recurrence) and (5) adverse effects.
Main results
We included 14 articles describing 13 studies, comprising 11 single-centre studies and two multi-centre studies. These studies involved
944 hands of 940 participants; of these, 93 participants were reported twice in separate articles describing early and late outcomes of
one trial. Three papers reported the outcomes of two trials comparing different procedures. One trial compared needle fasciotomy
versus fasciectomy (125 hands, 121 participants), and the other compared interposition firebreak skin grafting versus z-plasty closure
of fasciectomy (79 participants). The other 11 studies reported trials of technical refinements of procedures or rehabilitation adjuncts.
Of these, three investigated effects of postoperative splinting on surgical outcomes.
Ten studies (11 articles) were randomised controlled trials (RCTs) of varying methodological quality; one was a controlled clinical trial.
Trial design was unclear in two studies awaiting classification. All trials had high or unclear risk of at least one type of bias. High risks
of performance and detection bias were particularly common. We downgraded the quality of evidence (Grades of Recommendation,
Assessment, Development and Evaluation - GRADE) of outcomes to low because of concerns about risk of bias and imprecision.
Outcomes measured varied between studies. Five articles assessed recurrence; two defined this as reappearance of palpable disease and
two as deterioration in angular deformity; one did not explicitly define recurrence.
Hand function on the Disabilities of the Arm, Shoulder and Hand (DASH) Scale (scores between 0 and 100, with higher scores
indicating greater impairment) was 5 points lower after needle fasciotomy than after fasciectomy at five weeks. Patient satisfaction was
better after fasciotomy at six weeks, but the magnitude of effect was not specified. Fasciectomy improved contractures more effectively
in severe disease: Mean percentage reduction in total passive extension deficit at six weeks for Tubiana grades I and II was 11% lower
after needle fasciotomy than after fasciectomy, whereas for grades III and IV disease, it was 29% and 32% lower.
Paraesthesia (defined as subjective tingling sensation without objective evidence of altered sensation) was more common than needle
fasciotomy at one week after fasciectomy (228/1000 vs 67/1000), but reporting of complications was variable.
By five years, satisfaction (on a scale from 0 to 10, with higher scores showing greater satisfaction) was 2.1/10 points higher in the
fasciectomy group than in the fasciotomy group, and recurrence was greater after fasciotomy (849/1000 vs 209/1000). Firebreak skin
grafting did not improve outcomes more than fasciectomy alone, although this procedure took longer to perform.
One trial investigated four weeks of day and night splinting followed by two months of night splinting after surgery. The other two
trials investigated three months of night splinting after surgery, but participants in ’no splint’ groups with early deterioration at one
week were issued a splint for use. All three studies demonstrated no benefit from splinting. The two trials investigating postoperative
night splinting were suitable for meta-analysis, which demonstrated no benefit from splinting: Mean DASH score in the splint groups
was 1.15 points lower (95% confidence interval (CI) -2.32 to 4.62) than in the no splint groups. Mean total active extension in the
splint groups was 2.21 degrees greater (95% CI -3.59 to 8.01 degrees) than in the no splint groups. Mean total active flexion in the
splint groups was 8.42 degrees less (95% CI 1.78 to 15.07 degrees) than in the no splint groups.
Authors’ conclusions
Currently, insufficient evidence is available to show the relative superiority of different surgical procedures (needle fasciotomy vs
fasciectomy, or interposition firebreak skin grafting vs z-plasty closure of fasciectomy). Low-quality evidence suggests that postoperative
splinting may not improve outcomes and may impair outcomes by reducing active flexion. Further trials on this topic are urgently
required.
P L A I N L A N G U A G E S U M M A R Y
Surgery for Dupuytren’s disease of the fingers
Review question
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We conducted a review of the effects of surgery for people with Dupuytren’s disease of the fingers and found 13 studies with 940
participants; 93 participants were reported twice in separate articles describing early and late outcomes of one trial.
Background
Dupuytren’s disease is common. Patients develop scar-like tissue under the palmar skin of the hand that draws their fingers into the
palm and can affect function.
This condition can be surgically treated by cutting out the disease, then stitching the skin back into place (fasciectomy) or replacing it
with a graft of skin taken from elsewhere on the body (dermofasciectomy). Alternative approaches involve breaking the cord of disease
to straighten the finger. This can be done by moving a needle back and forth through the cord until it snaps, as when rubbing a rope
repeatedly over a rock (needle fasciotomy), or by injecting into it an enzyme that digests a piece of the cord (collagenase). This weakens
one spot, allowing the surgeon to snap the cord and straighten the finger. As the condition is related in part to genetics, it tends to
come back, even after successful treatment. As the latter two treatments leave the broken ends of the cord behind, recurrence may be
quicker after these procedures than after traditional excisional surgery. However, recovery might also be quicker. The most effective
treatment is unclear.
Study characteristics
After searching for all relevant studies up to May 2015, we found 13 studies (14 articles) that met our inclusion criteria. However,
only three compared different operation types. The others compared aspects of one operation type. One study presented early and late
outcomes.
Key results
What happens to people with Dupuytren’s disease up to five weeks after needle fasciotomy compared with fasciectomy?
• Hand function may be slightly better after needle fasciotomy than after fasciectomy (low-quality evidence).
• People who have had needle fasciotomy may be more satisfied than those who have had fasciectomy (low-quality evidence).
• Fasciectomy probably straightens fingers better than needle fasciotomy in people with advanced disease, but probably no difference
is apparent in people with milder disease (low-quality evidence).
• A feeling of tingling in the fingers is probably more common after fasciectomy than after needle fasciotomy during the first week after
treatment (low-quality evidence).
What happens to people with Dupuytren’s disease five years after needle fasciotomy compared with fasciectomy?
• Satisfaction may be better after fasciectomy than after needle fasciotomy (low-quality evidence).
• Recurrence may be more common after needle fasciotomy than after fasciectomy (low-quality evidence).
What happens to people with Dupuytren’s disease up to 36 months after z-plasty closure of a limited fasciectomy compared with use of small
‘firebreak’ skin grafts (a form of dermofasciectomy)?
• Little or no difference in outcomes is likely between patients who had z-plasty and those who had small skin grafts, although skin
graft procedures take longer to perform (low-quality evidence).
What happens to people with Dupuytren’s disease who wear a splint at night after surgery?
• Wearing a splint at night after surgery probably does not help to straighten fingers nor to improve hand function, and it may slightly
worsen the patient’s ability to make a full fist (low-quality evidence).
Side effects in people with Dupuytren’s disease after surgery and in those who wear a splint at night after surgery
Reporting of complications was variable. We often do not have precise information about side effects and complications, particularly
rare but serious side effects. Side effects may include altered feeling in the fingers or reduced ability to make a full fist. Rare complications
may include injury to the tendons that pull the fingers into the palm.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Comparison of operation types: early results of needle fasciotomy vs limited fasciectomy for Dupuytren’s disease
Patient or population: 125 hands in 121 participants with Dupuytren’s disease of the fingers for early outcomes (van Rijssen 2006)
Settings: single-centre Dutch study
Intervention: needle fasciotomy
Comparison: limited fasciectomy
Outcomesa Illustrative comparative risks* (95% CI) Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed riskb Corresponding risk
Limited fasciectomy Needle fasciotomy
DASH hand function score at
5 weeks
Major outcome group 1 (hand
function)
(scores between 0 and 100,
where 0 represents no impair-
ment in hand function and 100
represents maximum impair-
ment in hand function)
Mean DASH hand function
score in the fasciectomy
group was 16
DASH hand function score in
the fasciotomy group was 5
lower than in the fasciectomy
group
97
(1 study)
⊕⊕©©
Lowc
P value = 0.017 as quoted in
van Rijssen 2006
24/121 participants in the
study did not adequately com-
plete the DASH PROM tools
Insufficient detail in article to
allow calculation of 95% CI
(standard deviations not pro-
vided)
Unclear whether this is the
most appropriate time point for
study of ’early’ outcome
Patient satisfaction at 6
weeks
Major outcome group 2 (other
PROM)
(scores from ‘ ‘ 0 (no/very
negative) to 10 (yes/very pos-
itive)’’)
See comment See comment 121
(1 study)
⊕⊕©©
Lowd
Data not described in van
Rijssen 2006. Only level of
significance provided
P value = 0.002 as quoted in
van Rijssen 2006
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Early angular outcome at 6
weeks for Tubiana grade I
disease
(total passive extension deficit
(TPED) of the MCPJ, PIPJ and
DIPJ for preoperative contrac-
tures with a TPED of 0 to 45
degrees)
Early angular outcome at 6
weeks for Tubiana grade II
disease
(total passive extension deficit
(TPED) of the MCPJ, PIPJ and
DIPJ for preoperative contrac-
tures with a TPED of 45 to 90
degrees)
Early angular outcome at 6
weeks for Tubiana grade III
disease
(total passive extension deficit
(TPED) of the MCPJ, PIPJ and
DIPJ for preoperative contrac-
tures with a TPED of 90 to 135
degrees)
Early angular outcome at 6
weeks for Tubiana grade IV
disease
(total passive extension deficit
(TPED) of the MCPJ, PIPJ and
DIPJ for preoperative contrac-
tures with a TPED > 135 de-
grees)
Major outcome group 3 (early
objective measurement)
For Tubiana grade I disease,
mean percentage reduction in
TPED in the fasciectomygroup
was 82%
For Tubiana grade II disease,
mean percentage reduction in
TPED in the fasciectomygroup
was 78%
For Tubiana grade III disease,
mean percentage reduction in
TPED in the fasciectomygroup
was 75%
For Tubiana grade IV disease,
mean percentage reduction in
TPED in the fasciectomygroup
was 79%
For Tubiana grade I disease,
mean percentage reduction in
TPED in the fasciotomy group
was 11% lower than in the
fasciectomy group
For Tubiana grade II disease,
mean percentage reduction in
TPED in the fasciotomy group
was 11% lower than in the
fasciectomy group
For Tubiana grade III disease,
mean percentage reduction in
TPED in the fasciotomy group
was 29% lower than in the
fasciectomy group
For Tubiana grade IV disease,
mean percentage reduction in
TPED in the fasciotomy group
was 32% lower than in the
fasciectomy group
For grade I disease, 57
(1 study)
For grade II disease, 70
(1 study)
For grade III disease, 27
(1 study)
For grade IV disease, 10
(1 study)
⊕⊕©©
Lowe
For grade I disease, P value =
0.329 in van Rijssen 2006
For grade II disease, P value
= 0.071 in van Rijssen 2006
For grade III disease, P value
= 0.000 in van Rijssen 2006
For grade IV disease, P value
= 0.004 in van Rijssen 2006
Major outcome group 4 (re-
currence)
See comment See comment See comment See comment Not studied in van Rijssen
2006
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Paraesthesia at 1 week
Major outcome group 5 (ad-
verse effects)
Defined as ‘ ‘ tingling sensa-
tions at any part of the treated
digit without objective distur-
bance of sensation at the tip
of the digit’’ per hand
228 per 1000 67 per 1000 117
(1 study)
⊕⊕©©
Lowf
P value=0.013 in van Rijssen
2006
Relative effect not calculated
as only study available
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DASH: Disabilties of the Arm, Shoulder and Hand Scale; DIPJ: Distal interphalangeal joint; MCPJ: Metacarpophalangeal joint; PIPJ: Proximal interphalangeal joint;
PROM: Patient-reported outcome measures; RR: Risk ratio; TPED: Total passive extension deficit.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aRecurrence was not studied in van Rijssen 2006, as this article considered early outcomes only. Recurrence is a late effect, and
recurrence in this trial is considered in the next ’Summary of findings’ table.
bAll assumed risks are based on mean values for limited fasciectomy as reported in van Rijssen 2006.
cEvidence downgraded from high to low for DASH at 5 weeks because of significant attrition. van Rijssen 2006 had significant risk of
performance and detection biases, and imprecision.
dEvidence downgraded from high to low for patient satisfaction at 6 weeks, as scale used was not validated. van Rijssen 2006 had
significant risk of performance and detection biases, and imprecision.
eEvidence downgraded from high to low for early angular outcomes in grade I disease at 6 weeks, as van Rijssen 2006 had significant
risk of performance and detection biases, and imprecision.
f Paraesthesia at 6 weeks downgraded from high to low, as scale was not validated. van Rijssen 2006 had significant risk of performance
and detection biases, and imprecision.
6
S
u
rg
e
r
y
fo
r
D
u
p
u
y
tre
n
’s
c
o
n
tra
c
tu
re
o
f
th
e
fi
n
g
e
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Dupuytren’s disease may affect the hand and the sole of the foot.
In the hand, it is characterised by slow but progressive fibroprolif-
erative changes associated with the palmar aponeurosis, which lies
beneath the skin of the palm, and its extensions into the fingers
(Hurst 2000). Although it most commonly involves the ring and
little fingers, this disorder can affect any digit. In early stages, nod-
ules of Dupuytren’s tissue are formed in association with palmar
aponeurosis. These may coalesce to form cords of Dupuytren’s tis-
sue that run to the fingers. The cords may shorten and prevent full
extension of the fingers, thus stopping patients from placing their
hands flat on a surface. Patients may report difficulty in putting
on gloves, washing their face or performing other dextrous tasks.
If left untreated, this restriction of finger extension usually pro-
gresses, although the rate of progression is unpredictable. Changes
are irreversible without treatment (Luck 1959). Loss of motion,
particularly functional extension, results in activity limitations and
motivates the patient to explore surgical options (Pratt 2009).
The prevalence of Dupuytren’s disease varies with geographic lo-
cation and patient sex and age. It is unusual among individuals
younger than 50 years and is more common in men, although this
sex difference may diminish with increasing age. Its prevalence is
highest in men of Northern European origin, and in British men
and women over the age of 75 years may be as high as 18% and
9%, respectively (Early 1962).
The aetiology of Dupuytren’s disease is not fully understood.
Higher prevalence amongst family members has been accepted for
a long time (Yost 1955), and the disorder is associated with dia-
betes mellitus and smoking (Burge 1997). However, its proposed
association with epilepsy is unclear (Geoghegan 2004), and its re-
ported association with socio-economic factors and manual work
remains controversial (Early 1962; Herzog 1951).
Although typical patients experience slow progression of dis-
ease and respond well to intervention, some experience aggres-
sive disease progression, often from an early age, and earlier
recurrence - a condition referred to as ’Dupuytren’s diathesis’
(Hueston 1963). Benefits of treatment may vary according to
the anatomical location of Dupuytren’s disease within the hand.
One study reported more improved hand function when investi-
gators compared proximal interphalangeal joint (PIPJ) treatment
versus metacarpophalangeal joint (MCPJ) correction (Draviaraj
2004). However, achieving correction at the PIPJ is more difficult:
Whereas MCPJ contractures usually can be fully corrected with
surgery, PIPJ contractures frequently are incompletely corrected.
Consequently, heterogeneity is evident in terms of disease presen-
tation within the digits, response to surgery and functional benefit
derived from surgery.
No cure is known for Dupuytren’s disease; cure would require re-
moval of Dupuytren’s tissue from the palm of the hand and the
flexor surfaces of digits, as well as inhibition of subsequent dis-
ease formation. Instead, the primary goal of treatment is to excise,
divide, break or dissolve cords of Dupuytren’s tissue that are pre-
venting full finger extension, with the intention of improving or
correcting finger contracture (loss of extension). However, as some
cells that produceDupuytren’s tissue are inevitably left throughout
the hand and within the region of the treated cord, Dupuytren’s
contractures can form later at other sites in the hand (disease ex-
tension), or a ’recurrent contracture’ may develop within the op-
erative site. Treatment usually is offered before the affected finger
has contracted so far that hand function is significantly impaired,
because small contractures that have developed recently have a bet-
ter chance of correction than long-standing severe contractures,
which may have allowed secondary joint stiffness to develop in
the underlying ’flexed’ joints. A 30-degree MCPJ contracture is
often cited as a threshold for offering surgery (BSSH 2010). Such
a figure may be chosen, as less significant contractures might not
be expected to cause functional impairment, and because some be-
lieve that surgery itself might stimulate disease progression (Bisson
2003), although this theory has not been proved scientifically.
Non-operative strategies include radiotherapy, physical therapy
(typically involving splinting) and ultrasonography. The value of
radiotherapy for established contractures is uncertain, and out-
comes of splinting and ultrasonography are variable (Ball 2002;
Stiles 1966). A novel treatment approach consists of injecting col-
lagenase into Dupuytren’s cords, causing finger contracture (Hurst
2009). Collagenase synthesised by Clostridium histolyticum de-
grades collagen within Dupuytren’s cords, thus weakening them,
so they can be broken by forced extension of the affected finger on
the following day. The Food and Drug Administration (FDA) has
approved this treatment for use in the United States (FDA 2010),
and it is now licenced for use in the European Union, although
its effectiveness has not been fully evaluated (Thomas 2010). This
topic will be considered in a separate review.
Currently, the mainstay of treatment for Dupuytren’s contracture
is surgery, and many surgical options for Dupuytren’s disease are
available, beginning with Baron Dupuytren’s description of sur-
gical release of the contracture, performed without anaesthesia
in 1831 (Elliot 1999). Common management strategies are pre-
sented here by extent of surgery, starting with the least invasive
approach. Relative benefits and disadvantages are summarised.
Description of the intervention
Observation
Treatment is not mandatory, and after informed discussion of the
natural history of the condition and different treatment options,
a patient may elect observation of the hand. Patients with mild
disease and no functional impairment may also be observed. A
subgroup, labelled “non-Dupuytren’s disease” by one team of au-
7Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
thors, may not experience disease progression (Rayan 2005). Ob-
servation may be encountered as a comparator intervention rather
than as an experimental intervention.
Needle fasciotomy (aponeurotomy)
This involves blind division of the contracture with a hypodermic
needle (usually 25-gauge). This concept dates back to the time of
Dupuytren himself, and it has experienced a resurgence in pop-
ularity since the 1990s (Badois 1993). Benefits of this procedure
include that it can be performed in clinic on an outpatient ba-
sis, and so it may be cost-effective, and it may have a good rapid
recovery rate. Disadvantages include that needle fasciotomy may
have a significant recurrence rate of 75% or more at five years
(van Rijssen 2006a; van Rijssen 2012a), and the procedure carries
risks of tendon and digital nerve and artery damage. Although
most surgeons agree that this procedure has a role in managing
Dupuytren’s disease causing contracture of the MCPJ, it is less
popular for the treatment of Dupuytren’s cords that are causing
contracture of the PIPJ, because of associated risk of damage to
the digital nerves and flexor tendons in the finger and inability
to reliably release contractures of the PIPJ. A six-week follow-up
study suggested that it might be a reasonable alternative to limited
fasciectomy in the short-term management of selected cases such
as those involving elderly patients, with acceptance of significantly
higher recurrence after needle fasciotomy compared with fasciec-
tomy and the tendency for quicker recurrence. This was seen in
five-year follow-up data from the same study (van Rijssen 2012a).
Very limited fasciectomy (segmental aponeurectomy)
Small incisions are made over the portions of the Dupuytren’s
cord that are causing the contracture, and segments are excised
so that the finger straightens (Moermans 1991). No attempt is
made to remove all of the cord causing the contracture. Benefits
of this procedure are that it is relatively less invasive and involves
a quick (two-week or three-week) recovery period. However, it is
performed in an operating theatre and is thought to be associated
with a high rate of recurrence of Dupuytren’s contracture - up
to 38% (Moermans 1996) - which may occur because significant
deposits of Dupuytren’s tissue persist in the hand and the finger.
Although most surgeons agree that this procedure has a role in
Dupuytren’s disease in the palm of the hand that is causing con-
tracture of the MCPJ, it is less popular for treatment of cords in
the finger itself, which cause contracture of the PIPJ, because it
introduces risk of damage to the digital nerves and the inability to
reliably release contracture of the PIPJ.
Limited fasciectomy
Through this procedure, the surgeon aims to remove all of the
Dupuytren’s cord that is causing the finger contracture. Limited
fasciectomy has been the most popular treatment for Dupuytren’s
disease in the recent past, but it carries a significant recurrence
rate and involves a relatively long rehabilitation phase (four to six
weeks). Furthermore, it carries a small, although significant, risk
of complications such as diffuse finger stiffness, whichmay involve
not only the operated finger but the other fingers of the hand as
well. Recurrence following limited fasciectomy may exceed 20%
at five years (van Rijssen 2012a), possibly because disease-forming
cells retained in the subcutaneous fat and skinmay form ’recurrent’
contractures.
Dermofasciectomy
This is a more extensive procedure in which all of the Dupuytren’s
cord causing the contracture is excised. In addition, all subcuta-
neous fat and skin on the palmar aspect of the proximal andmiddle
pulp spaces of the finger (overlying the cord) are excised, leaving
only the flexor tendon sheath and the two neurovascular bundles.
The resultant skin defect is covered with a full-thickness skin graft,
which usually is harvested from the medial border of the forearm
or upper arm, the front of the elbow or the ulnar aspect of the
hand. Proponents of this procedure claim that through excision
of skin and subcutaneous fat that may be involved in Dupuytren’s
disease, the rate of recurrence of a Dupuytren’s contracture is re-
duced (Armstrong 2000). Many surgeons selectively use this pro-
cedure in young patients and in those with the ’diathesis’, in whom
risk of recurrence in later life is high. Specific disadvantages of der-
mofasciectomy include a longer rehabilitation phase and the need
to harvest a skin graft. Complications include loss of the skin graft
and, as for limited fasciectomy, the possibility of finger stiffness
and complex regional pain syndrome.
How the intervention might work
Surgery, consisting of excision or division of Dupuytren’s cord,
should allow immediate full extension of affected joints, as long as
the underlying joint has not developed a fixed flexion deformity
for other reasons (e.g. collateral ligament contraction, checkrein
ligament shortening, arthritis).
Why it is important to do this review
Comparative analysis of the outcomes of different surgical treat-
ment options for Dupuytren’s disease is needed to investigate
whethermore invasive procedures, such as dermofasciectomy, have
lower ’recurrent contracture’ rates, and whether any such benefit
is outweighed by a higher rate of adverse events (complications)
or an unacceptably longer or more difficult rehabilitation period.
Although comparison of different operative techniques is impor-
tant, it must be recognised that surgery is only part of a complex
intervention needed for the treatment of Dupuytren’s contracture.
The outcome of treatment may not be determined only by which
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type of surgery is performed, but also by the postoperative rehabil-
itation regimen provided (splintage and hand therapy) and other
treatment factors such as patient selection and site of contracture
(MCPJ alone, PIPJ alone or both joints together). Also the out-
come of Dupuytren’s surgery is usually defined by the ’recurrent
contracture rate’ (in contrast to ’disease extension’ to other digits,
the rate of which is not affected by surgery). Only a few studies
have assessed outcomes by using patient-centred outcome tools, or
have investigated the severity and length of postoperative recovery
from surgery.
O B J E C T I V E S
To assess the benefits and harms of different surgical procedures
for treatment of Dupuytren’s contracture of the index, middle,
ring and little fingers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and controlled
clinical trials (CCTs), irrespective of language or sample size.
Types of participants
Adult men and women from all ethnic origins, with or without
risk factors for Dupuytren’s disease, who had undergone a surgical
procedure for primary (not recurrent) Dupuytren’s contracture of
one or more of the index, middle, ring and little fingers.
Types of interventions
Any surgical intervention, including percutaneous needle fas-
ciotomy (aponeurotomy), very limited fasciectomy, limited fa-
sciectomy and dermofasciectomy. Comparators included alter-
native surgical procedures, placebo/sham surgery and other ac-
tive non-surgical treatments (collagenase injection, hand therapy,
physiotherapy, radiotherapy). We did not anticipate studies un-
dertaken to compare active treatment versus observation alone. If
we identified such studies, we planned to discuss them.
Types of outcome measures
The validity and reliability of any outcome measures commonly
used in Dupuytren’s disease have not been well studied. We have
listed below outcomes expected to be reported by study investi-
gators. We selected hand function as the top primary outcome,
as this represents an important patient-centred measure. In con-
trast, angular measurements are objective, surgeon-centred mea-
surements.
Major outcomes
• Level of hand function restored, as assessed by the
Disabilities of the Arm, Shoulder and Hand (DASH) Scale
(Hudak 1996), the Patient Evaluation Measure (PEM) (Macey
1995), grip strength measures or the Jebsen-Taylor Hand
Function Test (Jebsen 1969). We were uncertain about which
standardised outcome instruments we would encounter, but we
found that all were reported.
• Patient satisfaction and other patient-rated outcomes (such
as pain or health-related quality of life (HRQoL)). We will report
all measures encountered.
• Early angle outcomes and other objective outcomes. These
may involve (1) improvement in contracture immediately after
surgery - differences between finger angle measurements
immediately after surgery and preoperative finger angle
measurements, (2) residual contracture immediately after surgery
- as assessed by angle measurement (goniometry) or (3) early
results (as above) at time of discharge from care. Active or passive
angles may be reported. Angles may be presented per joint, or
per ray.
• Recurrence of Dupuytren’s disease/contracture in the
operated field. As recurrence is time-dependent, length of follow-
up is not standardised and a universally agreed upon definition
of recurrence is not available, we have described recurrence rates
and length of follow-up for each study in narrative format. We
planned to perform time-to-event analyses when we found
appropriate data. However, we did not expect that these data
would be available. We would have performed meta-analyses
only for studies with similar definitions of recurrence and
providing recurrence data at similar follow-up times after surgery
(’similar definitions of recurrence’ would include those with
recurrence involving a 20-degree to 30-degree increase in angle
compared with early discharge data or preoperative data).
Minimum length of follow-up for eligibility in this analysis was
18 months. This was decided on the basis of two considerations:
Shorter follow-up gives insufficient time for recurrence; and no
consensus has been reached to define minimum length of follow-
up, which varies widely in published studies, ranging from three
weeks to 13 years (Becker 2010).
• Adverse effects. Those anticipated included loss of finger
flexion, loss of finger sensation due to digital nerve injury,
vascular compromise, delayed healing and infection. As the
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extent of reported adverse events was unknown, we collected and
reviewed total adverse effects data. Review authors agreed to
focus on five key adverse events, should these prove to be
extensive.
Minor outcomes
• Economic costs of intervention. When provided, we would
assess these costs as total documented costs of the procedure and
rehabilitation. When time to recurrence was documented, we
would calculate cost per year of recurrence-free survival.
However, we anticipated that these data would not be commonly
available.
Search methods for identification of studies
We performed all searches on 17 September 2012. We re-ran
searches on 10 March 2014, and again on 20 May 2015, and we
updated the results.
Electronic searches
We searched the following electronic databases to find reports of
relevant RCTs and CCTs:
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (2012, Issue 8).
• British Nursing Index and Archive (BNI) - 1985 to
September 2012.
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) - 1981 to September 2012.
• EMBASE - 1980 to September 2012.
• Latin American Caribbean Health Sciences Literature
(LILACS) - 1982 to September 2012.
• Ovid MEDLINE - 1948 to September 2012.
• Ovid MEDLINE-In-Process and Other Non-Indexed
Citations - 1948 to September 2012.
• ProQuest (ABI/INFORM Global and Dissertations &
Theses) - all entries to September 2012.
• Institute for Scientific Information (ISI) Web of Science.
• clinicaltrials.gov.
We provided the full search strategy for CENTRAL in Appendix
1.
We combined the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for Identifying Randomised Tri-
als in MEDLINE: Sensitivity- and Precision-Maximizing Version
(2008 revision) (Lefebvre 2011): Ovid format (see Appendix 2 for
the full strategy). We combined the EMBASE (Appendix 3) and
CINAHL (Appendix 4) searches with trial filters developed by
the Scottish Intercollegiate Guidelines Network (SIGN) (SIGN
2011), and we applied no restrictions on the basis of language nor
date of publication.
We used variations of the Ovid MEDLINE search strategy to
search the other databases listed above (Appendix 5; Appendix 6;
Appendix 7; Appendix 8).
Searching other resources
We reviewed the reference lists of short-listed articles to identify
additional suitable studies, and we searched Web of Science to
identify studies that cited the items in the short list.We applied no
language restrictions, and we translated potentially eligible foreign
language studies.
Data collection and analysis
Selection of studies
From the title, abstract or descriptor, two review authors (JR, GB)
independently screened all abstracts to identify potential studies
for review, using a checklist of the criteria for inclusion (see Criteria
for considering studies for this review and Appendix 9). The two
review authors compared their lists of potential studies and pro-
duced an agreed upon short list. We obtained copies of the full
articles of papers on the agreed upon short list.
Two review authors (JR, GB) independently reviewed the full text
of abstracts of the ’agreed short list’ papers and identified those
suitable for inclusion, using the selection checklist (Criteria for
considering studies for this review). We resolved disagreements
by discussion and by referral to a third review author (TD). We
did not mask titles of journals nor names of study authors and
supporting institutions.
Data extraction and management
Two review authors (JR, CB) independently extracted data regard-
ing source, study design, intervention, population and outcomes
using a piloted form. We resolved disagreements by consensus af-
ter additional review by a third review author (TD).
Assessment of risk of bias in included studies
Two review authors (CB, JR) independently used the tool for
assessing risk of bias developed by The Cochrane Collaboration
(Higgins 2011). We assessed all seven domains (sequence genera-
tion, allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcome data,
selective outcome reporting and other issues) of this tool by al-
lowing classification of domains into ’high risk of bias’, ’low risk
of bias’ or ’unclear risk of bias’ (see Appendix 10). We judged by
outcome whenmost of the seven domains were deemed to provide
high risk or low risk. We resolved disagreements by discussion and
by referral to a third review author (TD). As we had anticipated
that few studies might employ blinding, we assessed use of blocked
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randomisation in unblinded studies as a source of ’other’ bias. In
blocked randomisation, investigators use sequences of allocation
assignment to balance enrolment between trial arms. In an un-
blinded study, this could contribute to risk of bias similar to that
seen with poor allocation concealment. We assessed the quality of
evidence by using Grades of Recommendation, Assessment, De-
velopment and Evaluation (GRADE) criteria, while taking into
account risks of bias.
Measures of treatment effect
If appropriate, we had planned to use standardised mean differ-
ences (SMDs) to combine different outcome measures from dif-
ferent trials (Hedges 1982).
In studies that reported dichotomous data, we planned to calculate
risk ratios (RRs) with 95% confidence intervals (CIs). For rare
events (< 10%), we planned to calculate Peto odds ratios with 95%
CIs. We planned to combine results for meta-analysis using fixed-
effect or random-effects models, depending on heterogeneity (see
Data synthesis).
Unit of analysis issues
Review authors expected that most studies would use the hand
as the unit of randomisation. Assessing outcomes such as hand
function would not be possible if individual fingers from the same
hand were used as the unit of randomisation. We recorded the unit
of randomisation (participant, hand, finger or unclear) for each
included study.
We did not expect to identify any cross-over studies, given that the
interventions described here are single-stage definitive treatments.
We expected to find no cluster-randomised studies.
Dealing with missing data
We anticipated two types of missing data: unreported and with-
drawn. If data were not reported in included trials, we contacted
study authors to request assistance. We planned to attempt no im-
putation.
Assessment of heterogeneity
If appropriate, we planned to test statistical heterogeneity by vi-
sually inspecting graphs and by performing Chi2 and I2 statisti-
cal tests. We considered a Chi2 test result with P value < 0.10 to
be significant. We classified an I2 test result greater than 50% as
showing substantial heterogeneity.
Assessment of reporting biases
To reduce the risk of reporting bias, we searched multiple sources,
including ProQuest (ABI/INFORM Global and Dissertations &
Theses), to identify all published and unpublished results.
We drew funnel plots to assess risk of publication bias.
We searched ISI Web of Science to identify relevant results that
had not been published. If we identified such work, we planned
to contact study authors to ask for a copy of the data.
Data synthesis
We compared data from selected studies by using the statisti-
cal software of The Cochrane Collaboration, Review Manager
(Review Manager 2011). If studies were sufficiently similar, we
planned to undertake a meta-analysis. If we needed to perform
meta-analyses, we planned to use the random-effects model.
When the same outcome measures were assessed with different
scales, we would use SMDs.
However, we anticipated that data from different studies would be
difficult to compare, and that a meta-analysis might be inappro-
priate. This would be the case particularly for the main outcome
of ’recurrence’ because of:
• differences in length of follow-up (recurrence rate increases
with length of follow-up); and
• differences in the definition of ’recurrence’.
We would use a fixed-effect model to combine data if outcomes
were homogeneous. If results were heterogeneous, we would un-
dertake subgroup analysis to identify the reasons for heterogeneity.
We would apply the random-effects model if we could find no
reason for heterogeneity.
If the nature of the included studies did not allow for statistical
analysis, we would use narrative (qualitative) summaries to present
study results.
Subgroup analysis and investigation of heterogeneity
If we found significant heterogeneity, we would not pool the data
and we would present a summary of methodological quality and
study results. We would consider reasons for heterogeneity by per-
forming subgroup analysis with regard to:
• length of time to follow-up;
• PIPJ and MCPJ outcomes separately, as it is well recognised
that MCPJ contractures correct better than PIPJ contractures;
• severity of disease before operation (when provided, we
expect that this will be given in the form of total passive
extension deficit (i.e. sum of the passive extension deficit at the
MCPJ and the PIPJ);
• number of joints involved; and
• postoperative treatment offered.
Sensitivity analysis
Outcome measures (e.g. the definition of recurrence) have been
explained differently (Becker 2010). If appropriate, we would per-
form a sensitivity analysis to examine whether results vary accord-
ing to different definitions used.
11Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We would undertake sensitivity analysis in cases of missing data
(e.g. intention-to-treat vs per-protocol analysis) to examine varia-
tions between approaches to analysis.
R E S U L T S
Description of studies
Results of the search
The search yielded 2464 references (see Figure 1). We removed
103 duplicates before screening abstracts.
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Figure 1. Study flow diagram.
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Of the remaining 2361 studies, we reviewed 16 full-text articles.
We could not classify two because the full-text article did not
adequately describe the study design, and it was not clear if studies
were randomised or pseudorandomised (Hazarika 1979; Ward
1976). Both articles are over 35 years old, and we could not obtain
clarification from study authors.
We included 14 full-text articles in the review (see Characteristics
of included studies and Bhatia 2002; Bulstrode 2004; Chignon-
Sicard 2012; Citron 2003; Citron 2005; Collis 2013; Degreef
2014; Howard 2009; Jerosch-Herold 2011; Kemler 2012;
McMillan 2012; Ullah 2009; van Rijssen 2006; van Rijssen
2012a), and we excluded 2264 studies. These 14 articles described
13 studies, with one study described in both an early outcome
paper (van Rijssen 2006) and a late outcome paper (van Rijssen
2012a).
Included studies
Eleven studies were single-centre studies; seven of these were based
in the United Kingdom and one each in Canada, France, Belgium
and New Zealand. Two articles were reports of one trial based in
the Netherlands. We identified two multi-centre studies (Jerosch-
Herold 2011; Kemler 2012). All five centres in Jerosch-Herold
2011 were located in the UK. Both centres in Kemler 2012 were
located in the Netherlands. All studies were published in English.
One study (Jerosch-Herold 2011) had an associated publication,
which presented the trial protocol (Jerosch-Herold 2008).
The 14 studies included 940 participants; the 93 reported in van
Rijssen 2012a were the same as those described in van Rijssen
2006. Thus 847 individual participants were recruited across all
studies.
Interventions studied
We identified no articles in which investigators compared surgery
versus observation.
Three articles described the outcomes of two trials that compared
different surgical procedures (Ullah 2009; van Rijssen 2006; van
Rijssen 2012a). One trial compared use of firebreak full-thickness
skin grafts (a type of dermofasciectomy) versus z-plasty closure of a
limited fasciectomy. Study authors refer to the original description
of firebreak grafts in Hueston 1984. Here, firebreak grafts were
described as small grafts strategically placed at flexion creases. In
contrast, traditional dermofasciectomy may involve resurfacing of
much larger areas of palmar skin (Seah 2012), which was achieved
by conducting a limited fasciectomy, then excising palmar skin to
accommodate the skin graft among those randomly assigned to this
cohort. The other two articles reported early and late outcomes,
respectively, for a single trial comparing needle fasciotomy versus
limited fasciectomy.
Four of the other eleven articles compared surgical incision and
wound management options (Bhatia 2002; Citron 2003; Citron
2005; Howard 2009). Bhatia 2002 and Howard 2009 compared
staple closure against suture closure, and absorbable versus non-
absorbable suture closures, respectively - both in limited fasciec-
tomy. Citron 2003 and Citron 2005 studied types of incisions
used for limited fasciectomy.
Three publications studied adjunctive treatments to surgery: One
investigated bathing the operation site in 5-fluorouracil versus
saline before closure (Bulstrode 2004), one compareduse of steroid
injections in conjunction with needle fasciotomy versus no ad-
junctive treatment (McMillan 2012) and the other compared ta-
moxifen versus placebo as neoadjuvant treatment in conjunction
with fasciectomy (Degreef 2014).
The other four trials studied non-invasive adjuncts to surgery:
Collis 2013, Jerosch-Herold 2011 and Kemler 2012 studied use
of postoperative splints versus no splints, and Chignon-Sicard
2012 investigated use of a fibrin- and platelet-rich fibrin plug as
a primary dressing versus a conventional low-adherence dressing
for open palm surgery.
These different interventions can be used to classify studies into:
• those studying different treatment options;
• those refining a treatment option (e.g. limited fasciectomy
incisions, closure types, invasive adjuncts, equipment usage); and
• those refining rehabilitation.
The first group comprises Ullah 2009, van Rijssen 2006 and van
Rijssen 2012a, three other articles describe refining rehabilitation
(Collis 2013; Jerosch-Herold 2011; Kemler 2012) and the remain-
ing eight explore ways to refine intraoperative techniques.
Inclusion and exclusion criteria
Criteria were not always specified. Two articles did not provide in-
clusion and exclusion criteria (Bhatia 2002;Howard 2009).Of the
other 12 studies, four specified age-related cutoffs for recruitment:
younger than 70 years (Bulstrode 2004) and over 18 years of age
(Chignon-Sicard 2012; Jerosch-Herold 2011; Kemler 2012). One
study did not describe the ratio of participant genders (Howard
2009). None of the others explicitly excluded potential partici-
pants on the basis of gender, although one comprised only male
participants (Bulstrode 2004).
Four studies excludedpatients undergoing revision surgery (Citron
2003; Citron 2005;Degreef 2014;McMillan 2012).Of these, one
study also excluded patients who had previously undergone other
types of hand surgery (McMillan 2012).
Three studies specified site of disease within the hand. Citron 2003
included only patients with palmar disease affecting theMCPJ. In
contrast, Ullah 2009 included only those with 30 or more degrees
of contracture at the PIPJ. Jerosch-Herold 2011 excluded thumb
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and first webspace treatments. Citron 2005 recruited participants
with Dupuytren’s disease in one ray only.
Some studies used exclusion criteria related to co-morbidities
that might influence outcome: Citron 2005, Ullah 2009, van
Rijssen 2006 and van Rijssen 2012a excluded patients with bleed-
ing tendencies. Diabetes mellitus was an exclusion criterion in
Chignon-Sicard 2012 and McMillan 2012.
Some specific criteria were related to study design. For example,
in Bulstrode 2004, participants had to receive treatment for two
rays in one procedure, as one was randomly assigned to receive 5-
fluorouracil, and the other to receive the control treatment of nor-
mal saline. In van Rijssen 2006 (and therefore van Rijssen 2012a),
participants had to have well-defined cords of disease. This is a
requirement for suitability for needle fasciotomy. Degreef 2014
excluded premenopausal women, patients taking anti-inflamma-
tory drugs, those with a history of malignancy and patients with
known allergy to tamoxifen.
Unit of analysis
The predicted unit of analysis was that randomisation would be
performed by ’hand’. This could lead to enrolment of the same
patient twice for surgery to each hand on separate occasions. van
Rijssen 2006 and van Rijssen 2012a included four such cases. In
contrast, in McMillan 2012, one participant with bilateral disease
was entered only once in the trial. Similarly, in Citron 2005, six
participants presented for randomisation twice for treatment of
bilateral disease. They were enrolled only once in the trial. In
the latter studies, the unit of randomisation was the ’participant’.
Other studies reported specific individualised methods. Bulstrode
2004 used an internal control, with one digit on a hand randomly
assigned to treatment, and another to control.
In terms of reporting recurrence, van Rijssen 2012a presented the
number of hands and the number of participants who had devel-
oped deformity greater than 20 degrees in one joint. Other studies
presented recurrence per participant (Citron 2003; Citron 2005;
Degreef 2014). The only other study investigating recurrence was
Ullah 2009, in which recurrence was described as the percentage
of fingers that showed recurrence, rather than as the proportion
of hands or participants.
Outcome measures
Outcomes measured varied between studies (Table 1). Specific
outcomes were used for particular studies.
Length of follow-up varied between papers. Those investigating
rehabilitation and early recovery varied from two-week follow-up
(Bhatia 2002; Howard 2009) to six-week follow-up (van Rijssen
2006). Late outcome papers varied in length of follow-up from
two years (Citron 2003; Citron 2005; Degreef 2014) to five years
(van Rijssen 2012a).
Hand function
Several trials presented patient-reported outcomes. These in-
cluded previously published patient-reported outcome measures
(PROMs) such as DASH scale scores (Collis 2013; Degreef 2014;
Jerosch-Herold 2011; van Rijssen 2006; van Rijssen 2012a) or the
PEM (Ullah 2009). The design of studies such as Bulstrode 2004,
with two digits on the same hand randomly assigned to different
groups, would have prevented meaningful interpretation of pa-
tient-reported outcomes such as hand function.
Patient satisfaction and other patient-rated outcomes
Studies comparing procedure types (van Rijssen 2006; van Rijssen
2012a) reported patient satisfaction. However, although statistical
significance was presented, investigators did not present full data.
Furthermore, they did not describe or reference the development,
validity and reliability of tools used to assess satisfaction. Collis
2013, Degreef 2014 and Jerosch-Herold 2011 also assessed sat-
isfaction. Kemler 2012 assessed patient-perceived change. Some
studies included self reported pain assessed by a visual analogue
scale (VAS) (Bhatia 2002; Howard 2009; Kemler 2012). One
study (Bhatia 2002) also reported patient-assessed wound appear-
ance, although development, validity or reliability of the tool used
was not described or referenced.
Early angles and other objective outcomes
Angular deformity was presented in different ways. Some investi-
gators presented active finger angles (Bulstrode 2004; Collis 2013;
Jerosch-Herold 2011; Kemler 2012; McMillan 2012), and others
presented passive angles (van Rijssen 2006; van Rijssen 2012a). In
some studies, it was not clear whether the angles presented were
active or passive (Citron 2003; Citron 2005; Degreef 2014; Ullah
2009). Presentation of angular measurements varied between early
and late outcomes of the same clinical trial (van Rijssen 2006;
van Rijssen 2012a). Other objective outcomes measured included
timings. Three studies presented analyses of time taken to perform
key tasks involved in surgery or postoperative care (Bhatia 2002;
Howard 2009; Ullah 2009). Bulstrode 2004 and Chignon-Sicard
2012 presented time to healing. Collis 2013 and Ullah 2009 stud-
ied grip strength.
Recurrence
Studies that reported comparisons of operative technique con-
sidered recurrence in late outcome papers (Citron 2003; Citron
2005; Degreef 2014; Ullah 2009; van Rijssen 2012a) and ex-
tension deficit at early outcome points (Ullah 2009; van Rijssen
2006). The definition of recurrence varied from reappearance of
palpable disease in the operated field (Citron 2003; Citron 2005)
to recurrent angular deformity (Degreef 2014; Ullah 2009; van
Rijssen 2012a).
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Within trials comparing different procedures, recurrence was de-
fined as an increase in joint angle of 20 or more degrees in van
Rijssen 2012a and was not explicitly defined in Degreef 2014
or Ullah 2009. However, researchers discussed ’progressive recur-
rence of contracture’, suggesting that angular deformity rather
than reappearance of palpable disease accounted for this.
Adverse effects
Adverse effect reporting varied from not studying complications
in a study of rehabilitation adjuncts (Jerosch-Herold 2011), to
describing ’no intraoperative complications’ (Bulstrode 2004) or
’no complications’ (Citron 2003), to describing and attempting to
quantify specific complications (Chignon-Sicard 2012). No stan-
dardisation was evident regarding which adverse effects were stud-
ied, even between similar studies.
Cost-effectiveness
No included studies presented formal cost-effectiveness analy-
ses, although several articles did assess cost-effectiveness. How-
ever, these studies were not randomised and were not pseudoran-
domised, so we excluded them. Three studies presented analyses
of time taken to perform aspects of surgery or postoperative care
(Bhatia 2002; Howard 2009; Ullah 2009) that would be expected
to have cost-effectiveness implications.
Summary
The primary objective of this review was to study trials compar-
ing different treatment options. This group comprises only three
papers describing two trials, and these two trials compared differ-
ent interventions using different inclusion and exclusion criteria.
Ullah 2009 compared small firebreak full-thickness skin grafting
versus z-plasty closure of limited fasciectomy for contractures in-
volving the PIPJ. In contrast, van Rijssen 2006 and van Rijssen
2012a described a trial comparing needle fasciotomy versus lim-
ited fasciectomy,with inclusion criteria including contractures that
may not necessarily affect the PIPJ.
Among trials refining intraoperative techniques, all compared dif-
ferent interventions. Among trials refining rehabilitation adjuncts,
two (Collis 2013; Jerosch-Herold 2011) investigated the same in-
tervention using comparable measures and time points, allowing
meta-analysis.
Excluded studies
In all, we excluded 450 studies on the basis of Q1 in Appendix 9
(i.e. they did not report the outcome of a clinical trial), and 1847
on the basis of Q2 in Appendix 9 (i.e. study participants had not
undergone surgery for Dupuytren’s disease of the fingers). We ex-
cluded two publications on the basis ofQ3 inAppendix 9, as inves-
tigators reported a study protocol but no results (Jerosch-Herold
2008 reported the study protocol for Jerosch-Herold 2011). We
excluded 34 studies on the basis of Q4 in Appendix 9 (i.e. two in-
terventionswere not compared, or no control groupwas included),
and nine studies on the basis ofQ5 inAppendix 9 (i.e. these studies
were not randomised and were not pseudorandomised). We have
described the studies in these three categories underCharacteristics
of excluded studies.
Three studies provided inadequate details in the abstract and ref-
erences to allow a decision (Gazdzik 1997; Slullitel 1987; Yoshida
1998), and we could not obtain the original paper. We excluded
them on this basis.
Risk of bias in included studies
We presented risk of bias for each study under Characteristics of
included studies and summarised study results in Figure 2 and
Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three trials did not explain the randomisation process used,
and one used alternation. The remaining nine studies used ac-
ceptable randomisation processes. Allocation concealment was
poorly described, with only three studies adequately describing
secure processes. Allocation concealment processes were robust
in Chignon-Sicard 2012, Citron 2005 and Jerosch-Herold 2011
only. The former two of these studies listed here described sealed,
sequentially numbered opaque envelopes, whereas Jerosch-Herold
2011 used telephone randomisation from another site but did not
specify how the random sequence was generated. Four other ar-
ticles used numbered sealed containers (envelopes or boxes) but
did not describe whether they were opaque (Degreef 2014; Ullah
2009; van Rijssen 2006; van Rijssen 2012a). Other studies pro-
vided similar inadequate details on concealment.
Blinding
As the treatment involved is a surgical procedure, it is acknowl-
edged that many trials are likely to be at high risk of performance
bias, as the surgical team performing the procedure cannot always
be blinded. In Degreef 2014, double-blinding was possible, as the
intervention was a medical adjunct to surgery. However, trials of
wound closure and adjuncts could defer randomisation until after
the corrective element of the procedure had been completed. This
was done only in Ullah 2009. Several other studies (Bhatia 2002;
Bulstrode 2004; Chignon-Sicard 2012; Howard 2009; McMillan
2012) could have deferred randomisation in this way to reduce
the impact of performance bias on other parts of the procedure,
but they did not.
Few studies explicitly described blinding of assessment. Bulstrode
2004 employed double-blinding of the participant as well as the
assessor. It is acknowledged that such blinding may be difficult
to achieve in comparisons of procedures that leave distinctive and
very different scar patterns on the hand (such as needle fasciotomy
and fasciectomy). Chignon-Sicard 2012 also described blinding
of outcome assessment.
Incomplete outcome data
Several studies did not formally describe attrition. van Rijssen
2012a, the study with the longest follow-up period, described sig-
nificantly different levels of attrition between groups, which could
have been influenced by treatment outcomes. Articles classified as
having ’unclear’ risk did not explicitly describe levels of attrition
experienced.
Selective reporting
One study (Howard 2009) excluded outliers despite formal testing
of the normality of data distribution and the decision to use non-
parametric statistics. The primary conclusion of the study could
become invalid with these outliers included in the analysis. Re-
searchers described no protocol for their exclusion. One further
study (Ullah 2009) listed the greatest number of secondary out-
comes but did not describe them in detail and presented some
only graphically.
Other potential sources of bias
As many studies were expected to be unblinded, we considered
risks of blocked randomisation in such studies. This risk was un-
clear in four articles (Chignon-Sicard 2012; Citron 2003; Collis
2013; Jerosch-Herold 2011), which provided inadequate detail to
allow exclusion of this risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1: comparison of operation types: early results of
needle fasciotomy vs limited fasciectomy for Dupuytren’s disease;
Summary of findings 2 Summary of findings table 2: comparison
of operation types: late results of needle fasciotomy vs limited
fasciectomy for Dupuytren’s disease; Summary of findings 3
Summary of findings table 3: comparison of operation types:
firebreak skin grafting vs z-plasty closure of fasciectomy for
Dupuytren’s disease;Summary of findings 4Summary of findings
table 4: refining rehabilitation: three months of postoperative
night splinting with hand therapy vs hand therapy alone for
rehabilitation following surgery for Dupuytren’s disease
Comparison of procedure types
Needle fasciotomy versus fasciectomy
One trial compared these procedures and reported early and late
outcomes separately (van Rijssen 2006; van Rijssen 2012a). The
early outcome article (van Rijssen 2006) reported 125 hands in
121 participants. The late outcome article (van Rijssen 2012a) in-
cluded 93 participants from the original cohort. This comparison
involved low-quality evidence related to study design limitations
and imprecision.
Hand function
Low-quality evidence suggests that hand function, as determined
by the DASH PROM, may be statistically significantly less after
needle fasciotomy than after fasciectomy at all time points up to
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five weeks following surgery (P value = 0.017 at five weeks) (van
Rijssen 2006). However, only 97 of 121 (80%) participants com-
pleted the PROM tool adequately to allow analysis. van Rijssen
2012a provided no evidence describing later functional outcomes.
Patient satisfaction and other patient-rated outcomes
Low-quality evidence indicates that patient satisfaction may be
significantly greater for the needle fasciotomy group than for the
fasciectomy group at six weeks (P value = 0.003 in van Rijssen
2006). Low-quality evidence also shows that by five years, patient
satisfaction had reversed; satisfaction was significantly greater for
fasciectomy (P value < 0.001 in van Rijssen 2012a), and overall
satisfaction was less among patients with recurrence (P value <
0.001 in van Rijssen 2012a). However, the tools used may not
have been robustly developed or validated, as has been discussed
(Description of studies), and data presented were incomplete.
Early angles and other objective outcomes
Low-quality evidence suggests that correction of total passive ex-
tension deficit was not different between procedures for milder
contractures (Tubiana stages I and II, which equates to total pas-
sive extension deficit across all joints less than 90 degrees) by six
weeks, but limited fasciectomy achieved significantly better cor-
rection for more severe contractures (Tubiana stages III and IV,
i.e. over 90 degrees of total passive extension deficit) (see Table 2).
Recurrence
Low-quality evidence indicates that recurrence may be signifi-
cantly greater five years after needle fasciotomy (84.9% of hands
after fasciotomy vs 20.9% of hands after fasciectomy; P value <
0.001 in van Rijssen 2012a).
Adverse effects
Low-quality evidence suggests that complication rates were simi-
lar between procedures in terms of infection, haematoma, wound
slough, skin fissure, sympathetic dystrophy, altered sensation, digi-
tal nerve injury, tendon injury and revision surgery. The incidence
of paraesthesia was statistically significantly greater after limited fa-
sciectomy than after fasciotomy one week after treatment (P value
= 0.013).
Cost-effectiveness
No published data were found comparing the cost-effectiveness of
needle fasciotomy and fasciectomy.
Summary
Evidence indicates that needle fasciotomy delivered better satisfac-
tion and function than fasciectomy at early outcomes, although
poor rates of completion of the PROMwere an issue. Fasciectomy
was more effective in correcting severe disease. Recurrence was
greater at five years after needle fasciotomy, although functional
outcomes had not been described. The cost-effectiveness of per-
forming multiple needle fasciotomies rather than a single fasciec-
tomy over a given period had not been studied. Study design lim-
itations and imprecision reduced the quality of the evidence. At
present, evidence in key areas is insufficient to show which treat-
ment is superior overall.
Dermofasciectomy versus fasciectomy
One study compared firebreak skin grafting versus direct closure
of fasciectomy (Ullah 2009) and provided low-quality evidence.
Investigators included 79 participants and presented a large quan-
tity of data only graphically.
Hand function
Hand function, as determined by the PEM PROM, was not dif-
ferent between fasciectomies and firebreak dermofasciectomies at
36 months. Investigators presented earlier time points only graph-
ically.
Patient satisfaction and other patient-rated outcomes
We found no published data that compared these outcomes for
fasciectomies and firebreak dermofasciectomies.
Early angles and other objective outcomes
Grip strength, angular deformity and motion at the PIPJ all cor-
related at 36 months. No differences between groups were evident
throughout the study, although the data supporting this were pre-
sented graphically only.
Recurrence
We noted no differences between firebreak dermofasciectomies
and fasciectomies in terms of recurrence, defined as progressive
contracture, and time to recurrence.
Adverse effects
We found no differences between procedures in terms of antibi-
otic requirement, skin necrosis, wound dehiscence, radial hypoaes-
thesia or reflex sympathetic dystrophy. We noted a significantly
greater incidence of ulnar hypoaesthesia after firebreak dermofa-
sciectomy.
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Cost-effectiveness
We identified no formal cost-effectiveness analysis data. However,
we noted that firebreak dermofasciectomy took significantly longer
to perform than fasciectomy involving z-plasty closure (79 vs 66
minutes; P value = 0.01).
Summary
Low-quality evidence indicates that firebreak dermofasciectomy
and fasciectomy with z-plasty closure performed similarly. Given
that firebreak dermofasciectomy took longer to perform, evidence
does not support its routine use. However, we cannot extend this
conclusion to other approaches to dermofasciectomy involving
larger skin grafts. We obtained no data on comparison of other
approaches versus dermofasciectomy and fasciectomy.
Technical refinements
Type of incision
Two articles studied incisions and included 30 and 100 partici-
pants, respectively. The first compared z-plasty closure versus di-
rect closure of a transverse incision for fasciectomy (Citron 2003).
The second compared a zig-zag (Bruner’s) incision with direct clo-
sure versus a longitudinal incision with z-plasty closure for fasciec-
tomy (Citron 2005). Researchers provided low-quality evidence
related to study design limitations and imprecision.
Hand function
We found no data that described this.
Patient satisfaction and other patient-rated outcomes
We found no data that described this.
Early angles and other objective outcomes
We found no evidence of differences between a zig-zag incision
and a z-plasty closure in terms of deformity or extension.
Recurrence
Low-quality evidence suggests that z-plasty closure of a palmar
fasciectomy had significantly less recurrence (reappearance of pal-
pable disease) than was seen with direct closure of a transverse
incision (P value < 0.01 when trial recruitment was stopped at
the interim analysis point in Citron 2003). Researchers reported
no differences in recurrence defined this way between a zig-zag
incision and a z-plasty closure.
Adverse effects
Investigators in Citron 2003 encountered no complications. In
Citron 2005, researchers comparing a zig-zag incision versus a z-
plasty reported no differences in total complications, algodystro-
phy and digital nerve injury.
Cost-effectiveness
We identified no formal cost-effectiveness analysis data.
Summary
Low-quality evidence supported z-plasty closure over direct closure
of transverse incisions for MCPJ cords and showed no differences
between a zig-zag incision and a z-plasty closure for fasciectomy.
Wound closure
Two studies (Bhatia 2002; Howard 2009) investigated wound clo-
sure. Bhatia 2002 compared staple closure versus non-absorbable
suture closure in 31 participants. Howard 2009 compared ab-
sorbable suture closure versus non-absorbable suture closure for
fasciectomy in 62 participants. Both trials provided low-quality
evidence related to study design limitations and imprecision.
Hand function
We found no data that described this.
Patient satisfaction and other patient-rated outcomes
Bhatia 2002 found no differences in patient-reported wound ap-
pearance at two weeks between those who received staples and
those given non-absorbable sutures. Removal of staples was more
painful than removal of non-absorbable sutures (P value = 0.008
in Bhatia 2002). Howard 2009 found no differences in visual ana-
logue scale (VAS) pain scores between absorbable and non-ab-
sorbable suture groups at the first postoperative visit.
Early angles and other objective outcomes
Staple closure was quicker to perform than non-absorbable suture
closure (P value < 0.001 in Bhatia 2002). Absorbable suture clo-
sure incurred less clinic time formanagement than non-absorbable
suture closure, once outliers were excluded (P value = 0.003 in
Howard 2009). However, exclusion of outliers from a non-para-
metric analysis may not have been appropriate and may invalidate
this finding.
Recurrence
We found no data that described this.
21Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adverse effects
Neither study performed formal analyses of differences in com-
plications between groups. However, complication rates were low
for both groups in both studies.
Cost-effectiveness
We identified no formal cost-effectiveness analysis data. Analysis
of timings as presented in Howard 2009 may not be robust, as has
been explained.
Summary
Staple closure may be quicker to perform than suture closure and
may achieve a comparable early wound appearance. However, re-
moval of staples may be more painful.
InHoward 2009, absorbable sutures achieved early outcomes com-
parable with those of non-absorbable sutures and were reported to
require less clinic time for postoperative management. However,
the evidence was incomplete, and the quality of evidence was low.
In particular, the main conclusion in Howard 2009 may not be
valid, as the statistical analysis performed may have been inappro-
priate.
Intraoperative adjuncts
Two studies investigated intraoperative adjuncts to surgery. Each
considered a different intervention. Bulstrode 2004 investigated
bathing a fasciectomy wound in 5-fluorouracil compared with
control, included 15 participants and provided low-quality evi-
dence. McMillan 2012 compared a postoperative series of steroid
injections as an adjunct to needle fasciotomy versus no injections
in 47 participants and provided low-quality evidence related to
study design limitations and imprecision.
One other study (Degreef 2014) considered a medical adjunct
spanning the perioperative period. Researchers compared tamox-
ifen versus placebo administered preoperatively and postopera-
tively as an adjunct to fasciectomy, included 30 participants and
provided low-quality evidence.
Hand function
Degreef 2014 reported no differences in hand function as assessed
by the DASH Scale at one year for tamoxifen versus placebo as
an adjunct to fasciectomy. We found no other data that described
this.
Patient satisfaction and other patient-rated outcomes
Degreef 2014 reported that satisfaction was not significantly dif-
ferent between groups at three months. We found no other data
that described this.
Early angles and other objective outcomes
Bulstrode 2004 found no differences between 5-fluorouracil treat-
ment and control treatment in terms of healing time, total ac-
tive motion and loss of extension. In McMillan 2012, a series of
steroid injections resulted in significantly greater percentage im-
provement in total active extension deficit at all time points. In
Degreef 2014, relative improvement in extension deficit, as quan-
tified by the Tubiana index, was significantly better in the tamox-
ifen group than in the placebo group.
Recurrence
Bulstrode 2004 found no differences between 5-fluorouracil treat-
ment and control treatment in terms of loss of extension nor total
activemotion at 18months.McMillan 2012 reported significantly
greater percentage improvement in total active extension deficit at
six months (65% correction for steroid group vs 41% for control
group; P value = 0.04) and in MCPJs and PIPJs considered sepa-
rately at six months. In Degreef 2014, only one participant in the
tamoxifen group experienced recurrence.
Adverse effects
Bulstrode 2004 and McMillan 2012 reported no complications.
Degreef 2014 provided a narrative description of adverse events.
Cost-effectiveness
We found no data that described this.
Summary
We found no evidence of benefit nor harm resulting from addition
of a 5-fluorouracil bath at completion of a fasciectomy, although
function and long-term outcomes (beyond 18 months) were not
studied. Evidence suggests that a series of steroid injections pro-
vided after needle fasciotomy may achieve and maintain better
correction of contractures than needle fasciotomy alone, although
we found no long-term data, and available evidence was of low
quality. Evidence indicates that a perioperative course of tamoxifen
may improve early correction of deformity, but that any potential
effect was lost by two-year follow-up.
Rehabilitation adjuncts
We identified four studies that investigated adjuncts that might aid
rehabilitation. Collis 2013 and Jerosch-Herold 2011 compared
three months of static postoperative splinting versus no postopera-
tive splinting. Kemler 2012 also investigated postoperative splint-
ing; the intervention arm underwent day and night splinting for
a month, then night splinting for two months, and the study in-
cluded 154 participants. Chignon-Sicard 2012 studied applica-
tion of fibrin- and platelet-rich fibrin plug to open palmar wounds
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after fasciectomy to identify whether this improved healing. All
studies provided low-quality evidence related to study design lim-
itations and imprecision.
The primary aim of this review had been to study operative tech-
niques. However, as rehabilitation adjuncts are components of
hand therapy in Dupuytren’s disease, these trials did meet the in-
clusion criteria specified in the protocol and have been included.
The published article for Collis 2013 did not provide all relevant
data.We contacted study authors, who provided the necessary data
for per-protocol analyses.
Hand function
Hand function, as assessed with the DASH PROM, was not af-
fected by postoperative splinting at three months, six months and
12 months (Jerosch-Herold 2011). Collis 2013 also found no ef-
fect when analysing individual time points up to three months
postoperatively. In the latter study, investigators combined time
points because no differences were found with a mixed-effect
model.
Meta-analysis of these two studies demonstrated no significant
heterogeneity at baseline (Analysis 1.1), and an intention-to-treat
analysis showed no differences in function between splint and no
splint groups at three-month follow-up (Analysis 2.1; Figure 4).
However, per-protocol groups were different from intention-to-
treat groups, as participants in the ’no splint’ group who expe-
rienced early re-contracture were then given a splint, and some
participants in the splint group were not compliant with splint-
ing (defined as self report of < 50% compliance). No differences
between ’splint’ and ’no splint’ groups were apparent when data
were analysed per protocol (Analysis 3.1).
Figure 4. Forest plot of comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-
treat), outcome: 2.1 DASH score at 3 months.
Patient satisfaction and other patient-rated outcomes
Patient satisfaction was not different among those receiving post-
operative splinting and those not receiving splinting, as assessed by
an 11-point verbal rating scale (Jerosch-Herold 2011). However,
the validity and reliability of this scale were not described or cited.
Patient-perceived changes were not significantly different between
groups in Kemler 2012.
Early angles and other objective outcomes
As with hand function, no significant heterogeneity between stud-
ieswas apparent at baseline (Analysis 1.2; Analysis 1.3). Total active
flexion and total active extension were not different among those
who received postoperative splinting at three, six or 12 months
(Jerosch-Herold 2011). Collis 2013 found no differences in total
active extension or flexion. Meta-analysis of three-month follow-
up results from both studies revealed no differences in total active
extension between splint and no splint groups (Analysis 2.2; Figure
5) but showed a significant difference in total active flexion, with
splint group participants achieving 8.42 degrees less total active
flexion than no splint group participants (Analysis 2.3; Figure 6).
As discussed in the section on hand function above, intention-
to-treat analyses were complicated by the fact that some in the
’no splint’ group were given a splint if they experienced early re-
contracture, and some in the ’splint’ group were non-compliant.
When meta-analyses were performed on the basis of per-protocol
data, no differences were found between groups in terms of total
active extension (Analysis 3.2), but the significant difference in
total active flexion shown in Analysis 2.3 was more pronounced
(Analysis 3.3).
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Figure 5. Forest plot of comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-
treat), outcome: 2.2 Total active extension at 3 months [degrees].
Figure 6. Forest plot of comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-
treat), outcome: 2.3 Total active flexion at 3 months [degrees].
Chignon-Sicard 2012 reported statistically significantly shorter
healing delay from application of a fibrin- and platelet-rich fibrin
plug to the open palmar wound versus control (median 24 days
vs median 29 days) but no differences in secondary endpoints.
Recurrence
Chignon-Sicard 2012, Collis 2013, Jerosch-Herold 2011 and
Kemler 2012 did not study recurrence.
Adverse effects
Chignon-Sicard 2012 studied bleeding and exudate and re-
ported no significant differences between intervention and control
groups. Investigators discussed other rare adverse events, includ-
ing wound and chest infection.
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Cost-effectiveness
No articles provided formal cost-effectiveness analysis data.
Summary
Evidence showing that postoperative splinting improves rehabili-
tation after fasciectomy or dermofasciectomy is lacking, but avail-
able evidence shows that three months of night splinting reduces
total active flexion at three months.
25Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Comparison of operation types: late results of needle fasciotomy vs limited fasciectomy for Dupuytren’s disease
Patient or population: 93 participants (van Rijssen 2012a)
Settings: single-centre Dutch study
Intervention: needle fasciotomy
Comparison: limited fasciectomy
Outcomes Illustrative comparative risks* (95% CI) Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Limited fasciectomy Needle fasciotomy
DASH hand function score at
5 years
Major outcome group 1 (hand
function)
(scores between 0 and 100,
where 0 represents no impair-
ment in hand function and 100
represents maximum impair-
ment in hand function)
See comment See comment See comment See comment Not studied in van Rijssen
2012a
Patient satisfaction at 5
years
Major outcome group 2 (other
PROM)
(scores between ‘ ‘ 1 (not at
all), 10 (excellent)’’)
Mean satisfaction score in fa-
sciectomy group was 8.3
Mean satisfaction score in fas-
ciotomy group was 2.1 lower
than in fasciectomy group
93
(1 study)
⊕⊕©©
Lowa
P value <0.001 as quoted in
van Rijssen 2012a
Likelihood of selecting treat-
ment again significantly higher
after fasciectomy (P value =
0.008)
Insufficient detail in article to
allow calculation of 95% CI
(standard deviations not pro-
vided)
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Major outcome group 3 (early
angular outcome)b
See comment See comment See comment See comment This major outcome group is
not relevant to a late outcome
comparison
Recurrence at 5 years
Major outcome group 4 (re-
currence)
Defined as reoperation or pro-
gressive angular deformity of
20 degrees in a successfully
treated joint
209 per 1000 849 per 1000 93
(1 study)
⊕⊕©©
Lowc
Progressive angular deformity
defined in van Rijssen 2006 as
an increase in TPED ≥ 30 de-
grees. In van Rijssen 2012a,
different definitions used (in-
crease of 20 degrees in a
successfully treated joint) in
other studies of Dupuytren’s
disease, such as Hurst 2009,
acknowledged and applied
P value <0.001 in van Rijssen
2012a
Relative effect not calculated,
as only study available
Recurrence rate influenced by
the definition of recurrence
used, and by length of follow-
up period
Major outcome group 5 (ad-
verse effects)d
see comment see comment see comment see comment Not discussed in van Rijssen
2012a; analysed in van
Rijssen 2006
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DASH: Disabilities of the Arm, Shoulder and Hand Scale; PROM: Patient-reported outcome measure; RR: Risk ratio; TPED: Total passive extension deficit.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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aQuality of evidence for patient satisfaction at 5 years downgraded from high to low because of significant risks of bias in van Rijssen
2012a, and as the result of imprecision.
bEarly angular outcomes and adverse effects not considered in this table, as these are relevant to early outcome assessment, and so are
included in the previous ’Summary of findings’ table.
cQuality of evidence for recurrence at 5 years downgraded from high to low because of significant risks of bias in van Rijssen 2012a,
and as the result of imprecision.
dEarly angular outcomes and adverse effects not considered in this table, as these are relevant to early outcome assessment, and so
are included in the previous ’Summary of findings’ table.
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Comparison of operation types: firebreak skin grafting vs z-plasty closure of fasciectomy for Dupuytren’s disease
Patient or population: 79 participants (Ullah 2009)
Settings: single-centre UK study
Intervention: firebreak skin grafting to close incision
Comparison: z-plasty closure of incision
Outcomes Illustrative comparative risks* (95% CI) Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
z-plasty Firebreak skin grafting
PEM hand function score at
3 years
Major outcome group 1 (hand
function)
(scores between 0 and 77,
where 0 represents no impair-
ment in hand function and 77
represents maximum impair-
ment in hand function)
See comment See comment 79
(1 study)
⊕⊕©©
Lowa
Data represented graphically
only; differences between
groups described as not sta-
tistically significant; no P value
provided
Major outcome group 2 (pa-
tient satisfaction and other
PROM)
See comment See comment See comment See comment Not studied in Ullah 2009
Correction of MCPJ and PIPJ
deformities at
2 weeks
Major outcome group 3 (early
angular outcomes)
All MCPJs fully corrected
Mean PIPJ correction 6 de-
grees in the z-plasty group
All MCPJs also fully corrected
Mean PIPJ correction no dif-
ferent (also 6 degrees) in the
skin graft group from the z-
plasty group
79
(1 study)
⊕⊕©©
Lowb
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Progressive contracture by 3
years
Major outcome group 4 (re-
currence)
109 per 1000 136 per 1000 79
(1 study)
⊕⊕©©
Lowc
P value = 0.17 in Ullah 2009
Rates assessed per finger (90
fingers treated among 79 par-
ticipants)
Hypoaesthesia
Major outcome group 5 (ad-
verse effects)
Radial digital nerve territory:
217 per 1000
Ulnar digital nerve territory:
217 per 1000
Radial digital nerve territory:
341 per 1000
Ulnar digital nerve territory:
455 per 1000
79
(1 study)
⊕⊕©©
Lowd
P value = 0.2 for radial digital
nerve territory in Ullah 2009
P value = 0.03 for ulnar digital
nerve territory in Ullah 2009
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; MCPJ: Metacarpophalangeal joint; PEM: Patient Evaluation Measure; PIPJ: Proximal interphalangeal joint; PROM: Patient-reported outcome measure; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aQuality of evidence for PEM hand function score at 3 years downgraded from high to low, as neither data nor P value was provided to
support statement, and as the result of imprecision.
b,c,dQuality of evidence downgraded from high to low because of risks of bias and imprecision.
3
0
S
u
rg
e
r
y
fo
r
D
u
p
u
y
tre
n
’s
c
o
n
tra
c
tu
re
o
f
th
e
fi
n
g
e
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Refining rehabilitation: three months of postoperative night splinting with hand therapy vs hand therapy alone for rehabilitation following surgery for Dupuytren’s disease
Patient or population: 210 participants with Dupuytren’s disease of the fingers in 2 studies (225 digits reported across all studies) (Collis 2013; Jerosch-Herold 2011)
Settings: multi-centre UK RCT and single-centre New Zealand RCT
Intervention: three months of night splinting in extension in addition to hand therapy (‘ ‘ splint’’)
Comparison: hand therapy alone (‘ ‘ no splint’’)
Outcomes Illustrative comparative risks* (95% CI) Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No splint Splint
DASH hand function score at
3 months
Major outcome group 1 (hand
function)
(scores between 0 and 100,
where 0 represents no impair-
ment in hand function and 100
represents maximum impair-
ment in hand function)
Mean DASH ranged across ’no
splint’ groups from
10.8 to 11
Mean DASH in ’splint’ groups
was 1.15 lower (95% CI -2.
32 to 4.62) than in ’no splint’
groups
205 participants
(2 studies)
⊕⊕©©
Lowa
Unclear whether this is the
most appropriate time point for
study of ’early’ outcome
Major outcome group 2 (pa-
tient satisfaction)
See comment See comment See comment See comment Not assessed in these studies
Total active extension at 3
months
Major outcome group 3 (early
objective measurement)
Total active extension (TAE) of
MCPJ, PIPJ and DIPJ; higher
value indicates loss of exten-
sion and a worse outcome
Mean TAE ranged across ’no
splint’ groups from
24 degrees to 33 degrees
Mean TAE in ’splint’ groups
was 2.21 degrees higher (95%
CI -3.59 to 8.01) than in ’no
splint’ groups
225 digits
(2 studies)
⊕⊕©©
Lowb
Unclear whether this is the
most appropriate time point for
study of ’early’ outcome
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Major outcome group 4 (re-
currence)
See comment See comment See comment See comment Not assessed in these studies
Total active flexion at three
months
Major outcome group 5 (ad-
verse effects)
Total active flexion (TAF) of
MCPJ, PIPJ and DIPJ; lower
value indicates loss of flexion
and a worse outcome
Mean TAF ranged across ’no
splint’ groups from
217.6 degrees to 245 degrees
Mean TAF in ’splint’ groups
was 8.42 degrees lower (95%
CI 1.78 to 15.07) than in ’no
splint’ groups
225 digits
(2 studies)
⊕⊕©©
Lowc
Conflicting findings from sub-
groups
Unclear whether this is the
most appropriate time point for
study of ’early’ outcome
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DASH: Disabilities of the Arm, Shoulder and Hand Scale; DIPJ: Distal interphalangeal joint; MCPJ: Metacarpophalangeal joint; PIPJ: Proximal interphalangeal joint;
RCT: Randomised controlled trial; TAE: Total active extension; TAF: Total active flexion.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
a,b,cQuality of evidence was downgraded from high to low because of risks of bias and imprecision.
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D I S C U S S I O N
Summary of main results
Outcomes measured
Review authors noted variation between studies in primary out-
comemeasures assessed. Although some of this might be expected,
for example, time taken for staple removal rather than recurrence
as a long-term outcome, the extent of variation within groups of
studies limits the usefulness of the data presented, as well as their
interpretation. Such variation is seen across lower-quality studies
as well. Providing no definition of recurrence, as was the case in
Ullah 2009, is commonplace (Becker 2010) and limits interpre-
tation of data.
Recurrence defined as the reappearance of palpable disease, as in
Citron 2003 andCitron 2005, is acknowledged as generating qual-
itative data (Werker 2012). When detection bias is a risk, as in
Citron 2003, the combination of an unblinded assessor and out-
comes defined in a binary but subjective manner might be ex-
pected to be unsound. Additionally, this outcome is not a sensible
option for studying fasciotomy, as palpable disease is never cleared
from the treated field in the first place. Therefore, its use in Citron
2003 is not appropriate.
Even within studies that use angular deformity to define outcomes
and recurrence, wide variation is evident in what exactly is mea-
sured and how it is described and presented (Ball 2013). Angles
may be presented as the passive angles obtained by an assessor, as
in van Rijssen 2006 and van Rijssen 2012a, or as active extension
achieved unsupported by the participant, as in McMillan 2012.
Such angles may differ, influencing study outcomes.
Although we could not perform meta-analysis to compare opera-
tion types because of the paucity of comparable trials, it is proba-
ble that even if additional data are generated in the future, meta-
analysis would not be possible without standardisation of follow-
up length and outcome measures used. As Dupuytren’s disease is
a slowly progressive condition (Luck 1959), recurrence is likely to
increase with longer periods of follow-up. Furthermore, an under-
standing of the natural history of the condition (Luck 1959) sug-
gests that recurrence defined as reappearance of palpable disease is
likely to be encountered earlier than recurrence defined as deterio-
rating angular deformity. These inconsistencies contribute to the
wide variation in recurrence rates reported in the existing literature
- from 0% to 71% (Becker 2010). Other groups have noted the
need for clarity and consistency (Werker 2012). This review reit-
erates this and calls for more detailed study of the validity and re-
liability of outcome measures to ensure that the most appropriate
outcomes are assessed at consistent and meaningful time points.
Furthermore, recurrence of palpable disease and recurrence of an-
gular deformity may not be truly relevant endpoints. Assessment
of hand function through patient-reported and patient-centred
measures may be more appropriate. Some of the studies included
in this review used patient-reported outcomes as a secondary end-
point.
Marked variation is evident in data reported by study authors as
secondary outcomes. In part, this is a result of the study ques-
tion selected, although outcomes handled as ’secondary’ measures
in studies were classified as appropriate primary outcome mea-
sures in this review, for example, patient-reported hand function.
However, trials of procedure types and technical refinement var-
ied in that some recorded numerous secondary measures (Ullah
2009) and others recorded virtually none other than complications
(McMillan 2012). In Ullah 2009, not all outcomes were reported
fully other than in graphs, raising an unclear possibility of report-
ing bias. Furthermore, even if the data had been fully reported, the
value of capturing all outcomes is not clear. One secondary out-
come measure of importance is assessment of health-related qual-
ity of life. Systems for analysing cost-effectiveness are informed
by data describing this, and data are captured by PROMs such as
the EuroQol 5 Domain scale (EuroQol-5D) (NICE 2008). Func-
tional outcomes represent patient-centred outcomes and may be
of pragmatic interest to commissioners of health care. Use of pa-
tient-reported data has been promoted nationally in theUK (Darzi
2008). This review cannot examine which of the range of PROMs
available for use in Dupuytren’s disease (Ball 2013) is most ap-
propriate for use in future research. Recent reviews have called
for further study of outcome measures (Ball 2013; Becker 2010;
Werker 2012). To date, only a few studies have included patient-
reported hand function. Data captured by the PEM inUllah 2009
were not described in detail in the paper. The DASH scale used in
Degreef 2014, van Rijssen 2006 and van Rijssen 2012a has been
the most popular measure across all studies of Dupuytren’s dis-
ease (Ball 2013). DASH data presented in van Rijssen 2006 did
not support the same conclusions as were reached by measuring
angles; needle fasciotomy fared better throughout early rehabili-
tation in terms of DASH scores, despite the fact that fasciectomy
arguably provided better correction of angular deformity in gen-
eral. Thus, the conclusions drawn in this paper are likely to vary
considerably, depending on which outcome is considered to be
of primary importance. van Rijssen 2012a did not include corre-
sponding late outcome function data. Given the value of health-
related quality of life data for accepted cost-effectiveness analyses
(NICE 2008), and the wide variation in reporting of angles in the
literature (Ball 2013), future pragmatic trials might consider pa-
tient-reported outcomes as the primary outcome measures, with
joint angles demoted in importance. Furthermore, such a change
might support the design of pragmatic studies. Ullah 2009 mea-
sured a variety of secondary outcomes. However, separating the
primary outcome from complications may limit the clinical appli-
cability of research findings. If an intervention achieves low rates
of recurrence but does so with significant risk of complications
such as chronic regional pain syndrome, cold intolerance and loss
of grip strength or flexion, it may still fail to achieve meaningful
clinical improvement for patients and cost-effectiveness for com-
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missioning bodies. Reports of early and late outcomes of the trial
comparing fasciectomy and needle fasciotomy (van Rijssen 2006;
van Rijssen 2012a) considered patient satisfaction, as did a trial
on the use of tamoxifen as an adjunct to surgery (Degreef 2014),
although the validity and reliability of these assessments were not
clear. As already discussed for angular measurements, further work
is urgently required to establish the validity and reliability of pa-
tient-reported outcome measures.
Comparison of procedure types
We identified no studies in which surgery was compared with ob-
servation. Given that Dupuytren’s disease typically is slowly pro-
gressive and is not life-threatening, such comparisons would be
informative.
The trial reported in van Rijssen 2006 and van Rijssen 2012a
suggests that needle fasciotomy may achieve angular correction
comparable with that of limited fasciectomy for milder Tubiana I
and II contractures, but inferior correction for Tubiana III and IV
contractures. However, this procedure leads to less functional im-
pairment in the early postoperative phase (up to five weeks in van
Rijssen 2006), earlier recovery and higher early patient satisfac-
tion. By five years, it results in significantly higher recurrence and
lower satisfaction than fasciectomy. The considerable difference
in recurrence rates between fasciotomy and fasciectomy may be
interpreted as demonstrating that fasciotomy is an inferior treat-
ment. However, attrition bias may have affected late outcomes,
and late functional outcomes were not recorded. As fasciotomy is
less invasive, with quicker recovery (van Rijssen 2006), recurrence
alonemay not comprehensively describe late functional outcomes.
Patient satisfaction is an important outcome formeasurement, but
perhaps it should be combined with, rather than used instead of,
valid measures of hand function, as it might be influenced by fac-
tors besides the functional efficacy of treatment.
It might not be reasonable to expect needle fasciotomy, a demon-
strably less invasive procedure that can be repeated for recurrent
disease (van Rijssen 2012b), to achieve a durable effect comparable
with that achieved by the more invasive fasciectomy. A more prag-
matic study might consider early and late functional outcomes in
groups randomly assigned to receive one fasciectomy or multiple
needle fasciotomies over a period of years, with cost-effectiveness
calculated on the basis of functional outcomes and treatment path-
way expenses.
Comparison of fasciectomy with z-plasty closure versus firebreak
skin grafting in Ullah 2009 revealed no differences between
groups, other than prolonged operation time for skin grafting.
This suggests that firebreak skin grafting may not prevent recur-
rence better than fasciectomy. However, dermofasciectomy com-
prises a spectrum, with small skin grafts used as firebreaks in Ullah
2009 at one end, and much more extensive skin grafts at the other
end (Seah 2012). Thus, further comparison between limited fa-
sciectomy and dermofasciectomy is needed.
Investigations of postoperative splinting
This was the only area in which meta-analysis was possible. Re-
cruitment for Collis 2013 began before Jerosch-Herold 2011 was
published. However, earlier publication of the trial protocol for
Jerosch-Herold 2011 (Jerosch-Herold 2008) facilitated standard-
isation. Indeed, this was the only published trial protocol that we
identified. Advanced publication of trial protocols is encouraged,
as thismay facilitate future standardisation of outcome assessment.
The functional outcome studied here was absolute DASH score at
three months (rather than change in DASH score from preopera-
tive to postoperative state), as preoperative DASH scores were not
different between splint and no splint groups in either of the in-
cluded studies (Collis 2013; Jerosch-Herold 2011). Furthermore,
this final result represents patients’ functional performance at that
time. Individual splinting results from all three trials showed no
beneficial or adverse effects over postoperative splinting, but meta-
analysis of two of these studies showed statistically significant loss
of flexion at three months caused by splinting. Whether the mag-
nitude of the difference noted is of clinical significance, or whether
it persists later in the rehabilitation period, is unclear. However,
given the potentially expanded utilisation of resources needed to
produce andmaintain splints, we do not support their routine use.
Investigations of other questions
The primary objective of this review was to identify trials com-
paring different types of procedures. However, we have identified
other trials within Dupuytren’s disease surgery and have grouped
them into trials investigating technical refinements of procedures,
and trials investigating rehabilitation adjuncts. Although these
studies might be considered tangential to the central aim of this
review, we believe that appraising them is important to ensure
that this review has been comprehensive, and that aspects of study
methods and reporting have contributed to the conclusions pre-
sented here. In particular, analysing these studies informs impli-
cations for future research in this field. For example, Citron 2005
was the only included study that adequately described a randomi-
sation process that used envelopes to provide adequate allocation
concealment. As with studies comparing types of procedures, lack
of comparable studies limited the performance of meta-analysis.
Bhatia 2002 demonstrated that staple closure of fasciectomies may
be quicker than suture closer, while showing that it resulted in
greater pain at staple removal. However, this finding may be lim-
ited by the risk of bias in this study regarding allocation conceal-
ment. Citron 2003 was stopped early because a higher rate of re-
currence was noted after direct closure than after z-plasty closure.
However, this difference had reached P value < 0.1 rather than
the more conventional P value < 0.05; also, this study had been
assigned high risk of bias related to use of alternation rather than
randomisation, and as the result of performance and detection bi-
ases.
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Overall completeness and applicability of
evidence
This systematic review has identified very few high-quality studies
of Dupuytren’s disease surgery. Among the included trials, fewer
still compareddifferent procedures, and others studied refinements
in practice. Despite the availability of many current treatment
options for years or decades, the paucity of studies suggests that
research in this field lacks direction.
Quality of the evidence
The quality of methods varied between studies. More modern
studies were generally at less risk of bias. Our assessment of per-
formance bias might be controversial. To minimise the potential
for the surgeon to influence the quality of the procedure, we in-
cluded blinding of the surgeon during the procedure. Achieving
this blinding may be extremely challenging and may not be pos-
sible in some studies. However, clear efforts were made in Ullah
2009 to standardise the surgical procedure as far as possible, with
randomisation performed intraoperatively rather than preopera-
tively, unlike other studies investigating an intervention of rele-
vance to closing stages of the procedure. As a result of these efforts,
excision of disease that might be considered the ’correction’ por-
tion of the surgery was not subject to lack of blinding, and only
wound closure was unblinded. Taking such steps when possible
may limit the effects of performance bias.
In addition to risks of bias related to study design limitations,
we further downgraded the quality of evidence as the result of
imprecision, with most comparisons based on one or two studies
with small sample sizes and wide confidence intervals.
Potential biases in the review process
We explained deviations from the published protocol in the sec-
tion titled Differences between protocol and review. We believe
that these differences are minor and have not influenced review
outcomes. Although we took explicit steps to review conference
proceeding abstracts, wemay havemissed unpublished data.How-
ever, given the paucity of trial data identified across all sources, we
believe it is unlikely that a significant volume of relevant data has
not been published.
Agreements and disagreements with other
studies or reviews
We are not aware of similar reviews on this topic. However, expert
opinion supports the need for further research in this area to inform
clinical practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has identified insufficient evidence to inform the roles
of different procedures (needle fasciotomy, fasciectomy, interpo-
sition firebreak skin grafting or z-plasty closure of fasciectomy)
in the surgical treatment of patients with Dupuytren’s disease of
the fingers, beyond discussion of the limited results of individual
studies. Further research in this field is urgently required.
The meta-analysis performed here questions routine use of splint-
ing following surgery for Dupuytren’s disease, and this warrants
further research. Splinting may impair outcomes by reducing ac-
tive flexion, although this is not clear from the data presented here.
Furthermore, given the unclear role of splinting in early re-con-
tracture, splinting should be considered on an individual patient
basis until further evidence becomes available.
Implications for research
A marked paucity of randomised controlled trials on Dupuytren’s
disease surgery has been noted. This is the case for comparisons of
different treatment procedures, of which several are currently in
use, including needle fasciotomy, fasciectomy and dermofasciec-
tomy. The role of each of these treatments in relation to other
treatments is not currently supported by high-quality evidence.
Evidence related to collagenase will be considered in a separate
review.
Given the need to justify the cost-effectiveness of treatments in
modern healthcare systems, it might be advisable to target research
towards comparisons of different procedures. At present, clinical
practice in Dupuytren’s disease is not informed by high-quality
evidence. Logically, studies aimed at refining treatment might be
better conducted only once the effectiveness and roles of different
treatments have been established.
To date, design quality and reporting of trials in Dupuytren’s dis-
ease surgery remain generally poor, with only a few examples show-
ing good practice.
Future trials should ensure that risks of bias are minimised. As
acknowledged, performance bias may prove difficult to minimise
in some studies. That said, certain components of the studies in-
cluded here have set precedents for processes by which risk of bias
in random sequence generation, allocation concealment and out-
come detection can be minimised. Future studies should endeav-
our to employ such robust processes, and to report them clearly.
Advanced publication of trial methods was encountered only once
in this review, but it facilitated standardisation and meta-analysis.
This practice is encouraged.
Before needed trials are undertaken, further study of outcome
measures is needed to establish their validity and reliability for use
in Dupuytren’s disease. Once this has been done, consensus and
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consistency of outcome choices and time points of assessment are
needed to ensure standardisation with other studies.
A C K N OW L E D G E M E N T S
The authors would like to thank the Cochrane Musculoskeletal
Group for support provided, and Tamara Rader and Louise Falzon
for assistance in developing the search strategy.
R E F E R E N C E S
References to studies included in this review
Bhatia 2002 {published data only}
Bhatia R, Blackshaw G, Barr V, Savage R. Comparative
study of “staples versus sutures” in skin closure following
Dupuytren’s surgery. Journal of Hand Surgery (British &
European Volume) 2002;27(1):53–4.
Bulstrode 2004 {published data only}
Bulstrode NW, Bisson M, Jemec B, Pratt AL, McGrouther
DA, Grobbelaar A. A prospective randomised clinical trial
of the intra-operative use of 5-fluorouracil on the outcome
of Dupuytren’s disease. Journal of Hand Surgery (British &
European Volume) 2004;29(1):18–21.
Chignon-Sicard 2012 {published data only}
Chignon-Sicard B, Georgiou CA, Fontas E, David S,
Dumas P, Ihrai T, et al. Efficacy of leukocyte- and platelet-
rich fibrin in wound healing: a randomized controlled
clinical trial. Plastic and Reconstructive Surgery 2012;130(6):
819e–29e.
Citron 2003 {published data only}
Citron N, Hearnden A. Skin tension in the aetiology of
Dupuytren’s disease; a prospective trial. Journal of Hand
Surgery (British & European Volume) 2003; Vol. 28, issue
6:528–30.
Citron 2005 {published data only}
Citron ND, Nunez V. Recurrence after surgery for
Dupuytren’s disease: a randomized trial of two skin
incisions. Journal of Hand Surgery (British & European
Volume) 2005; Vol. 30, issue 6:563–66.
Collis 2013 {published data only}
Collis J, Collocott S, Hing W, Kelly E. The effect of night
extension orthoses following surgical release of Dupuytren
contracture: a single-center, randomized, controlled trial.
Journal of Hand Surgery (American Volume) 2013;38(7):
1285–94.
Degreef 2014 {published data only}
Degreef I, Tejpar S, Sciot R, De Smet L. High-dosage
tamoxifen as neoadjuvant treatment in minimally invasive
surgery for Dupuytren disease in patients with a strong
predisposition toward fibrosis: a randomized controlled
trial. Journal of Bone & Joint Surgery (American Volume)
2014;96(8):655–62.
Howard 2009 {published data only}
Howard K, Simison AJM, Morris A, Bhalaik V. A
prospective randomised trial of absorbable versus non-
absorbable sutures for wound closure after fasciectomy for
Dupuytren’s contracture. Journal of Hand Surgery (British &
European Volume) 2009;34(5):618–20.
Jerosch-Herold 2011 {published data only}
Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson
D, Barrett E, Vaughan SP. Night-time splinting after
fasciectomy or dermo-fasciectomy for Dupuytren’s
contracture: a pragmatic, multi-centre, randomised
controlled trial. BMC Musculoskeletal Disorders 2011;12:
136.
Kemler 2012 {published data only}
Kemler MA, Houpt P, van der Horst CMAM. A pilot
study assessing the effectiveness of postoperative splinting
after limited fasciectomy for Dupuytren’s disease. Journal
of Hand Surgery (British & European Volume) 2012;37(8):
733–7.
McMillan 2012 {published data only}
McMillan C, Binhammer P. Steroid injection and needle
aponeurotomy for Dupuytren contracture: a randomized,
controlled study. Journal of Hand Surgery (American Volume)
2012;37:1307–12.
Ullah 2009 {published data only}
Ullah AS, Dias JJ, Bhowal B. Does a ’firebreak’ full-thickness
skin graft prevent recurrence after surgery for Dupuytren’s
contracture? A prospective, randomised trial. Journal of
Bone and Joint Surgery (British Volume) 2009;91(3):374–8.
van Rijssen 2006 {published data only}
van Rijssen AL, Gerbrandy FSJ, Linden HT, Klip H,
Werker PMN. A comparison of the direct outcomes of
percutaneous needle fasciotomy and limited fasciectomy for
Dupuytren’s disease: a 6-week follow-up study. Journal of
Hand Surgery (American Volume) 2006;31(5):717–25.
van Rijssen 2012a {published data only}
van Rijssen AL, ter Linden H, Werker PM. Five-year results
of a randomized clinical trial on treatment in Dupuytren’s
disease: percutaneous needle fasciotomy versus limited
fasciectomy. Plastic and Reconstructive Surgery 2012;129(2):
469–77.
36Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies excluded from this review
Atroshi 2014 {published data only}
Atroshi I, Strandberg E, Lauritzson A, Ahlgren E, Walden
M. Costs for collagenase injections compared with
fasciectomy in the treatment of Dupuytren’s contracture: a
retrospective cohort study. BMJ Open 2014;4(1):e004166.
Barros 1997 {published data only}
Barros F, Barros A, Almeida S. Dupuytren’s diseases:
evaluation of 100 cases [Enfermidade de Dupuytren:
avaliaçião de 100 casos]. Revista Brasileira de Ortopedia
1997;32(3):177–83.
Bendon 2012 {published data only}
Bendon CL, Giele HP. Collagenase for Dupuytren’s disease
of the thumb. Journal of Bone and Joint Surgery (British
Volume) 2012;94(10):1390–2.
Braga Silva 1999 {published data only}
Braga Silva J, Fernandes H, Fridman M. The open palm
technique in severe Dupuytren contracture [A técnica da
palma aberta na contratura grave de Dupuytren]. Revista
Brasileira Ortopedia 1999;34:51–4.
Braga Silva 2002 {published data only}
Silva Braga J, Kuyven CR, Martins PDE. The open palm
technique in severe Dupuytren’s contracture. Revista da
Sociedade Brasileira de Cirurgia Plástica 2002;17:61–5.
Castro 1981 {published data only}
Castro O. Dupuytren’s contracture: surgical treatment
by the open palm technique [Contratura de Dupuytren:
tratamento cirurgico pela tecnica “open palm”]. Ceará
Médico 1981;3:13–7.
Cervero 2013 {published data only}
Cervero RS, Ferrando NF, Jornet JP. Use of resources
and costs associated with the treatment of Dupuytren’s
contracture at an orthopedics and traumatology
surgery department in Denia (Spain): collagenase
Clostridium histolyticum versus subtotal fasciectomy. BMC
Musculoskeletal Disorders 2013;14:293.
Craft 2011 {published data only}
Craft RO, Smith AA, Coakley B, Casey WJ, Rebecca AM,
Duncan SFM. Preliminary soft-tissue distraction versus
checkrein ligament release after fasciectomy in the treatment
of Dupuytren proximal interphalangeal joint contractures.
Plastic and Reconstructive Surgery 2011;128(5):1107–13.
Dias 2013 {published data only}
Dias JJ, Singh HP, Ullah A, Bhowal B, Thompson JR.
Patterns of recontracture after surgical correction of
Dupuytren disease. Journal of Hand Surgery (American
Volume) 2013;38:1987–93.
Dib 2008 {published data only}
Dib CC, Gervais J, Monteiro CGZ, Mendoza E, Pimentel
RAP. Dupuytren’s disease: our conduct [Doença de
Dupuytren: nossa conduta]. Revista da Sociedade Brasileira
de Cirurgia Plástica 2008;23(4):290–3.
Dickie 1967 {published data only}
Dickie WRD. Dupuytren’s contracture. A review of the
late results of radical fasciectomy. British Journal of Plastic
Surgery 1967;20:311–4.
Erne 2014 {published data only}
Erne HC. Downgrading severe stages of Dupuytren’s
contracture to simplify partial aponeurectomy using
percutaneous needle fasciotomy. Plastic and Reconstructive
Surgery 2014;133(1):79e–80e.
Evans 2002 {published data only}
Evans RB, Dell PC, Fiolkowski P. A clinical report of
the effect of mechanical stress on functional results after
fasciectomy for Dupuytren’s contracture. Journal of Hand
Therapy 2002;15:331–9.
Ferry 2013 {published data only}
Ferry N, Lasserre G, Pauchot J, Lepage D, Tropet Y.
Characteristics of Dupuytren’s disease in woman. A study of
67 cases [Particularités de la maladie de Dupuytren chez la
femme. À propos de 67 cas]. Annales de Chirurgie Plastique
et Esthetique 2013;58(6):663–9.
Galbiatti 1995 {published data only}
Galbiatti JA, Fiori JM, Mansano RT, Durigan JA. Treatment
of Dupuytren’s illness using straight longitudinal incision
completed with “Z” drawn surgery [Tratamento da moléstia
de Dupuytren pela técnica de incisão longitudinal reta,
complementada com Z–plastia]. Revista Brasileira Ortopedia
1995;30:207–12.
Glassey 2001 {published data only}
Glassey N. A study of the effect of night extension splintage
on post-fasciectomy Dupuytren’s patients. British Journal of
Hand Therapy 2001;6:89–94.
Gomes 1984 {published data only}
Gomes CA. Dupuytren’s disease: experience of partial
fasciectomy in 11 cases [Doenca de Dupuytren: experiencia
da fasciectomia parcial em 11 casos]. Ceára Médico 1984;6:
79–81.
Halliday 1966 {published data only}
Halliday DR, Lipscomb PR, Seldon TH. Fasciectomy
and controlled hypotension in treatment of Dupuytren’s
contracture. American Journal of Surgery 1966; Vol. 111:
282–5.
Herrera 2013 {published data only}
Herrera FA, Benhaim P, Suliman A, Roostaeian J, Azari
K, Mitchell S. Cost comparison of open fasciectomy
versus percutaneous needle aponeurotomy for treatment of
Dupuytren contracture. Annals of Plastic Surgery 2013;70
(4):454–6.
Hovius 2011 {published data only}
Hovius SE, Kan HJ, Smit X, Selles RW, Cardoso E,
Khouri RK. Extensive percutaneous aponeurotomy and
lipografting: a new treatment for Dupuytren disease. Plastic
and Reconstructive Surgery 2011;128:221–8.
Jerosch-Herold 2008 {published data only}
Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson
D. Splinting after contracture release for Dupuytren’s
37Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
contracture (SCoRD): protocol of a pragmatic, multi-
centre, randomized controlled trial. BMC Musculoskeletal
Disorders 2008;9:62.
Larson 2012 {published data only}
Larson D. The relative responsiveness of patient-rated
outcome measures in evaluating clinical change after
Dupuytren’s surgery: a literature review and prospective
observational pilot study. Hand Therapy 2012;17(3):52–9.
Malta 1984 {published data only}
Malta MC, Vianna SE, Schott PC. Open palm technique
in Dupuytren’s contracture [A tecnica da palma aberta na
contratura de Dupuytren]. Revista Brasileira Ortopedia
1984;19:46–8.
Malta 2013 {published data only}
Malta MC, Alves MdPT, Malta LMdA. Open palm
technique in Dupuytren’s disease treatment [A técnica da
palma aberta no tratamento da doença de Dupuytren].
Revista Brasileira de Ortopedia 2013;48(3):246–50.
Moraes Neto 1996 {published data only}
Moraes Neto GP, Chambriard C, Knackfuss I, Osório
L, Couto P. Percutaneous fasciotomy for the correction
of metacarpophalangeal joint derformity on Dupuytren’s
disease [Fasciotomia percutânea na correção da deformidade
da articulação metacarpofalângica na contratura de
Dupuytren]. Revista Brasileira Orthopedia 1996;31:347–50.
Nancoo 2007 {published data only}
Nancoo T, Kang N, Kambhampati B, Floyd D, White J,
Mc Grouther DA. Severe Dupuytren’s PIP joint contracture
treated by a two stage technique: a pilot study. Proceedings
of the 10th Congress of the International Federation of
Societies for Surgery of the Hand; 7th Congress of the
International Federation of Societies for Hand Therapy.
Bologna: Medimond International Proceedings, 2007:
303–7.
Nydick 2013 {published data only}
Nydick JA, Olliff BW, Garcia MJ, Hess AV, Stone JD.
A comparison of percutaneous needle fasciotomy and
collagenase injection for Dupuytren disease. Journal of
Hand Surgery (American Volume) 2013;38(12):2377–80.
Orbezo 1999 {published data only}
Orbezo F, Trueba DC, Alvarez IE, Preciado Aceves ME,
Sale H Larrañaga SS, Navarrete Alvarez JM. Dupuytren’s
diasease: report of 100 cases: experience of surgical
treatment [Reporte de 100 casos, experiencia de tratamiento
quirúrgico en el Hospital Español de México y el Hospital
San Eloy: Vizcaya España]. Revista Mexicana de Ortopedia y
Traumatología 1999;13:269–72.
Ould-Slimane 2013 {published data only}
Ould-Slimane M, Guinet V, Foulongne E, Melconian
A, Beccari R, Milliez PY, et al. Razemon’s lateral digital
rotation flap in severe Dupuytren contracture of the fifth
finger [Le lambeau de rotation latéro–digital de Razemon
dans les formes graves de la maladie de Dupuytren du
cinquième rayon]. Chirurgie de la Main 2013;32(5):
317–21.
Pereira 2012 {published data only}
Pereira A, Massada M, Sousa R, Silva C, Trigueiros M,
Lemos R. Percutaneous needle fasciotomy in Dupuytren’s
contracture: is it a viable technique?. Acta Orthopaedica
Belgica 2012;78(1):30–4.
Pesco 2008 {published data only}
Pesco MS. A comparison of palmar static digit extension
splinting and dorsal block dynamic digit extension splinting
with postoperative Dupuytren’s contracture release.
Proceedings of the 7th Congress of the Asian Pacific
Federation of Societies for Surgery of the Hand. Bologna:
Medimond International Proceedings, 2008:25–30.
Pess 2012 {published data only}
Pess GM,Pess RM, Pess RA. Results of needle aponeurotomy
for Dupuytren contracture in over 1,000 fingers. Journal of
Hand Surgery (American Volume) 2012;37(4):651–6.
Reuben 2006 {published data only}
Reuben SS, Pristas R, Dixon D, Faruqi S, Madabhushi
L, Wenner S. The incidence of complex regional pain
syndrome after fasciectomy for Dupuytren’s contracture:
a prospective observational study of four anesthetic
techniques. Anesthesia and Analgesia 2006;102:499–503.
Rives 1992 {published data only}
Rives K, Gelberman R, Smith B, Carney K. Severe
contractures of the proximal interphalangeal joint in
Dupuytren’s disease: results of a prospective trial of operative
correction and dynamic extension splinting. Journal of
Hand Surgery (American Volume) 1992;17:1153–9.
Skoff 2004 {published data only}
Skoff HD. The surgical treatment of Dupuytren’s
contracture: a synthesis of techniques. Plastic and
Reconstructive Surgery 2004; Vol. 113:540–4.
van Rijssen 2012b {published data only}
van Rijssen AL, Werker PMN. Percutaneous needle
fasciotomy for recurrent Dupuytren disease. Journal of
Hand Surgery (American Volume) 2012;37(9):1820–3.
Vollbach 2013 {published data only}
Vollbach FH, Walle L, Fansa H. Dupuytren’s disease -
patient satisfaction and functional results one year after
partial fasciectomy and injection of collagenase [Morbus
Dupuytren - Patientenzufriedenheit und funktionelle
Ergebnisse ein Jahr nach partieller Aponeurektomie und
Injektion von Kollagenase]. Handchirurgie Mikrochirurgie
Plastische Chirurgie 2013;45(5):258–64.
von Campe 2012 {published data only}
von Campe A, Mende K, Omaren H, Meuli-Simmen C.
Painful nodules and cords in Dupuytren disease. Journal of
Hand Surgery (American Volume) 2012;37(7):1313–8.
White 2012 {published data only}
White JW, Kang SN, Nancoo T, Floyd D, Kambhampati
SBS, McGrouther DA. Management of severe Dupuytren’s
contracture of the proximal interphalangeal joint with use
of a central slip facilitation device. Journal of Hand Surgery
(European Volume) 2012;37(8):728–32.
38Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies awaiting assessment
Gazdzik 1997 {published data only}
Gazdzik T, Wasilewski Z. Results of surgical treatment
for Dupuytren contracture [Wyniki leczenia operacyjnego
przykurczu Dupuytrena]. Chirurgia Narzadow Ruchu i
Ortopedia Polska 1997;62(5):375–9.
Hazarika 1979 {published data only}
Hazarika EZ, Knight MT, Frazer-Moodie A. The effect
of intermittent pneumatic compression on the hand after
fasciectomy. The Hand 1979;11(3):309–14.
Slullitel 1987 {published data only}
Slullitel M. Our behaviour in Dupuytren’s disease [Nuestro
comportamiento ante la enfermedad de Dupuytren /
Dupuytren´ s disease]. Revista de la Asociación Argentina de
Ortopedia y Traumatología 1987;52(1):103–6.
Ward 1976 {published data only}
Ward CM. Oedema of the hand after fasciectomy with
or without tourniquet. The Hand 1976; Vol. 8, issue 2:
179–85.
Yoshida 1998 {published data only}
Yoshida K, Yamada Y, Hara H, Yamanaka K, Inoue H.
The surgical treatment for Dupuytren’s contracture. 7th
Congress of the International Federation of Societies for
Surgery of the Hand. Bologna: Medimond International
Proceedings, 1998:307–11.
Additional references
Armstrong 2000
Armstrong JR, Hurren JS, Logan AM. Dermofasciectomy
in the management of Dupuytren’s disease. Journal of Bone
and Joint Surgery (British Volume) 2000;82(1):90–4.
Badois 1993
Badois FJ, Lermusiaux JL, Masse C, Kuntz D. Non-surgical
treatment of Dupuytren’s disease using needle fasciotomy
[Traitement non chirurgical de la maladie de Dupuytren
par aponévrotomie à l’aiguille]. Revue du rhumatisme (Ed.
française) 1993;60(11):808–13.
Ball 2002
Ball C, Nanchahal J. The use of splinting as a non-surgical
treatment for Dupuytren’s disease. British Journal of Hand
Therapy 2002;7(3):76–8.
Ball 2013
Ball C, Pratt A, Nanchahal J. Optimal functional outcome
measures for assessing treatment for Dupuytren’s disease: a
systematic review and recommendations for future practice.
BMC Musculoskeletal Disorders 2013;14:131.
Becker 2010
Becker GW, Davis TR. The outcome of surgical treatments
for primary Dupuytren’s disease - a systematic review.
Journal of Hand Surgery (European Volume) 2010;35(8):
623–6.
Bisson 2003
Bisson MA, McGrouther DA, Mudera V, Grobelaar
OA. The different characteristics of Dupuytren’s disease
fibroblasts derived from either nodule or cord: expression of
alpha-smooth muscle actin and the response to stimulation
by TGF-beta 1. Journal of Hand Surgery (British & European
Volume) 2003;28(4):351–6.
BSSH 2010
British Society for Surgery of the Hand. BSSH Evidence for
Surgical Treatment (BEST). 1: Dupuytren’s disease. http:/
/www.bssh.ac.uk/education/guidelines/dd˙guidelines.pdf
(accessed 29 August 2012).
Burge 1997
Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and
the risk of Dupuytren’s contracture. Journal of Bone and
Joint Surgery (British Volume) 1997;79(2):206–10.
Darzi 2008
Darzi A. High Quality Care for All: NHS Next Stage
Review Final Report. London: TSO, 2008.
Draviaraj 2004
Draviaraj KP, Chakrabarti I. Functional outcome after
surgery for Dupuytren’s contracture: a prospective study.
Journal of Hand Surgery (American Volume) 2004;29(5):
804–8.
Early 1962
Early PF. Population studies in Dupuytren’s contracture.
Journal of Bone and Joint Surgery (British Volume) 1962;44:
602–13.
Elliot 1999
Elliot D. The early history of Dupuytren’s disease. Hand
Clinics 1999;15(1):1-19.
FDA 2010
US Food, Drug Administration. FDA approves Xiaflex
for debilitating hand condition. http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/
ucm199736.htm (accessed 29 August 2012).
Geoghegan 2004
Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R.
Dupuytren’s disease risk factors. Journal of Hand Surgery
(British Volume) 2004;29(5):423–6.
Hedges 1982
Hedges LV. Fitting continuous models to effect size data.
Journal of Educational Statistics 1982;7(4):245–70.
Herzog 1951
Herzog EG. The aetiology of Dupuytren’s contracture.
Lancet 1951;1(6668):1305–6.
Higgins 2011
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions, Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. www.cochrane-
handbook.org.
Hudak 1996
Hudak PL, Amadio PC, Bombardier C. Development of an
upper extremity outcome measure: the DASH (Disabilities
of the Arm, Shoulder and Hand) [corrected]. The Upper
39Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Extremity Collaborative Group (UECG). American Journal
of Industrial Medicine 1996;29(6):602–8.
Hueston 1963
Hueston JT. The Dupuytren’s diathesis. In: Hueston J
editor(s). Dupuytren’s Contracture. Edinburgh: E & S
Livingstone, 1963:51–63.
Hueston 1984
Hueston JT. ’Firebreak’ grafts in Dupuytren’s contracture.
Australia and New Zealand Journal of Surgery 1984;54:
277–81.
Hurst 2000
Hurst LC, Badalamente MA. Histopathology and cell
biology. In: Tubiana R, Leclerq C, Hurst L, Badalamente
M, Mackin E editor(s). Dupuytren’s Disease. London:
Martin Dunitz, 2000.
Hurst 2009
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss
RN, Kaplan FT, Meals RA, et al. Injectable collagenase
clostridium histolyticum for Dupuytren’s contracture. New
England Journal of Medicine 2009;361(10):968–79.
Jebsen 1969
Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ,
Howard LA. An objective and standardized test of hand
function. Archives of Physical Medicine and Rehabilitation
1969;50:311–9.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions, Version
5.1.0 [updated March 2011]. The Cochrane Collaboration,
2011. www.cochrane-handbook.org.
Luck 1959
Luck JV. Dupuytren’s contracture: a new concept of the
pathogenesis correlated with surgical management. Journal
of Hand Surgery (American Volume) 1959;41(4):635–64.
Macey 1995
Macey AC, Burke FD. Outcomes of hand surgery. Journal
of Hand Surgery (European Volume) 1995;20-B:841–55.
Moermans 1991
Moermans JP. Segmental aponeurectomy in Dupuytren’s
disease. Journal of Hand Surgery (British Volume) 1991;16
(3):243–54.
Moermans 1996
Moermans JP. Long-term results after segmental
aponeurectomy for Dupuytren’s disease. Journal of Hand
Surgery (British Volume) 1996;21B(6):797–800.
NICE 2008
NICE. Guide to the Methods of Technology Appraisal.
London: NICE, 2008.
Pratt 2009
Pratt AL, Byrne G. The lived experience of Dupuytren’s
disease of the hand. Journal of Clinical Nursing 2009;18:
1793–802.
Rayan 2005
Rayan GM, Moore J. Non-Dupuytren’s disease of the
palmar fascia. Journal of Hand Surgery (British and European
Volume) 2005;30(6):551–6.
Review Manager 2011 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.1. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2011.
Seah 2012
Seah MK, Harry L, Davidson D. A three-digit
dermofasciectomy for Dupuytren’s disease. Hand Surgery
2012;17:109–10.
SIGN 2011
Scottish Intercollegiate Guidelines Network. Search
Filters (last modified: 16/09/11). http://www.sign.ac.uk/
methodology/filters.html. SIGN 2011, (accessed 29 August
2012).
Stiles 1966
Stiles PJ. Ultrasonic therapy in Dupuytren’s contracture.
Journal of Bone and Joint Surgery (British Volume) 1966;48
(3):452–3.
Thomas 2010
Thomas A, Bayat A. The emerging role of Clostridium
histolyticum collagenase in the treatment of Dupuytren
disease. Journal of Therapeutics and Clinical Risk
Management 2010;6:557–72.
van Rijssen 2006a
van Rijssen AL, Werker PM. Percutaneous needle
fasciotomy in Dupuytren’s disease. Journal of Hand Surgery
(British Volume) 2006;31(5):498–501.
Werker 2012
Werker PM, Pess GM, van Rijssen AL, Denkler K.
Correction of contracture and recurrence rates of Dupuytren
contracture following invasive treatment: the importance of
clear definitions. Journal of Hand Surgery (American Volume)
2012;37:2095–105.
Yost 1955
Yost J, Winters T, Fett HC. Dupuytren’s contracture: a
statistical study. American Journal of Surgery 1955;90(4):
568–71.
∗ Indicates the major publication for the study
40Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bhatia 2002
Methods Single-centre UK study
Randomised controlled trial
Recruitment between June 2000 and March 2001
Participants 31 participants
28:3 male/female ratio
Mean age: 61 years
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions Automated staple device closure
vs
Polybutester nonabsorbable suture closure
Outcomes • Time taken for closure (rate per centimetre of wound) (recorded by independent
observer)
◦ Staples quicker than sutures (P value < 0.001)
• Visual analogue scale (VAS) pain on removal score (patient reported, at 1 week
postop)
◦ Pain greater for staple removal than for suture removal (P value = 0.008)
• Wound appearance grade at 1 week and at 2 weeks (recorded by unblinded
surgeon)
◦ No differences between groups
• Patient-reported wound appearance at 2 weeks (patient reported)
◦ No differences between groups
• Complications reported? yes
• Details: 1 superficial wound infection treated with antibiotics; “no other
complications”
Notes Length of follow-up: 2 weeks
Low-quality evidence due to risk of bias regarding allocation concealment and impreci-
sion
No funding sources acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) High risk Not discussed in paper; use of unsecured
random numbers table assumed
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Bhatia 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 of 5 endpoints reported with complete
data; 1 of 5 not reported (wound appear-
ance category at 2 weeks)
Selective reporting (reporting bias) Low risk 4 of 5 endpoints reported with complete
data; 1 of 5 not reported (wound appear-
ance category at 2 weeks)
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk 3 of 5 assessments performed by surgeon or
reported by participant; 1 other
Bulstrode 2004
Methods Single-centre UK study
Randomised controlled trial
Recruitment dates not specified
Participants 15 participants
All male
Mean age: 61 years
Inclusion criteria: yes: age < 70 years, Luck involutional stage, ≥ 2 rays on hand affected
Exclusion criteria: not specified
Interventions Intraoperative wound bath in 5-FU
vs
Wound bath in normal saline
Outcomes • Time to wound healing
◦ No differences between groups
• MCPJ, PIPJ and total active motion: preoperative, 3 months, 18 months
◦ No differences between groups
• Loss of extension per ray: preoperative, 3 months, 18 months
◦ No differences between groups
◦ Measurements for all 3 outcomes performed by the same blinded therapist
• Complications reported? yes
• Details: “no intraoperative complications”
Notes Length of follow-up: 18 months
Low-quality evidence due to risk of bias and imprecision
Funded by the RAFT Institute of Plastic Surgery; no conflicts of interest declared
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Bulstrode 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Envelopes containing randomisation
Allocation concealment (selection bias) Unclear risk Unmarked envelopes; unclear whether
sealed or opaque
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeon administering
treatment not blinded; study described as
double-blinded: participant and assessor
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Measurements performed by blinded ther-
apist
Chignon-Sicard 2012
Methods Single-centre French study
Randomised controlled clinical trial
Recruitment between 2007 and 2010
Participants 68 participants
54 male:10 female; 4 excluded after randomisation not described
Mean age: 61.4 (SD 8.8) years for intervention group; 66.0 (SD 7.7) years for control
group
Inclusion criteria: yes: “healthy individuals older than 18 years without any comorbidity
who had been scheduled for electiveMcCash (open palm) surgery forDupuytren disease”
Exclusion criteria: yes: “Patients allergic to one of the dressing’s components, with di-
abetes mellitus type 1, who were undergoing cancer treatment, who were pregnant, or
who were unable to participate in follow-up visits were excluded”
Interventions Leucocyte- and platelet-rich fibrin platelet concentrate applied to wound
vs
Petroleum jelly mesh applied to wound
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Chignon-Sicard 2012 (Continued)
Outcomes • Healing delay
◦ Statistically significantly shorter healing delay in intervention group
compared with control group (median 24 days vs median 29 days)
• Pain (numerical visual analogue scale)
◦ No significant differences between groups at day 1, 7, 14, 21 or 28
• Bleeding (absent/slight/moderate/abundant)
◦ No significant differences between groups at day 7, 14 or 21
• Wound exudate (absent/slight/moderate/abundant)
◦ No significant differences at days 7 and 21; significantly more exudate in
control group at day 14
• Complications reported? yes
• Details: 1 wound infection in control group; 1 pulmonary infection in
intervention group
Notes Length of follow-up: 60 days
Low-quality evidence due to risk of bias and imprecision
Funding source: academic grant from the French Ministry of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Envelopes containing randomisation from
a “predefined randomiza-
tion list, constructed through random per-
muted blocks”
Allocation concealment (selection bias) Low risk “sealed, sequentially numbered, opaque en-
velopes containing treatment allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% loss to follow-up; split between groups
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Blocked randomisation employed in sin-
gle-blinded study (blinding of outcome as-
sessment only)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Randomisa-
tion performed before procedure; surgeon
probably unblinded throughout operative
procedure, including fasciectomy compo-
nent of procedure
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All assessors blinded
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Citron 2003
Methods Single-centre UK study
Pseudorandomised controlled clinical trial
Recruitment between 1996 and 2000
Participants 30 participants
24 male:6 female
Mean age (at diagnosis): 67 years for treatment group; 66 years for control group
Inclusion criteria: yes: “Dupuytren’s contracture of a single ray confined to the palm and
affecting only the MCPJ, a single cord of Dupuytren’s tissue, no previous surgery for
Dupuytren’s disease in that ray, agreement to surgery”
Exclusion criteria: not specified
Interventions Longitudinal incision closed with z-plasty
vs
Transverse incision
Outcomes • Recurrence (reappearance of palpable disease)
◦ Lower recurrence in z-plasty group than in direct closure group (P value < 0.
1)
• MCPJ flexion deformity: preoperative, postoperative
◦ No statistical analysis presented
◦ Both outcomes measured by 5 different unblinded assessors over the course
of the study; outcomes assessed at 2 years postop
• Complications reported? yes
• Details: “no complications”
Notes Mean length of follow-up: 2 years (range 2.0 to 3.5)
Low-quality evidence, as pseudorandomised and at high risk of bias and imprecision
No funding sources acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternation rather than randomisation
Allocation concealment (selection bias) High risk Alternation rather than randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% loss to follow-up but balanced be-
tween groups
Selective reporting (reporting bias) Low risk Primary outcomes reported
Other bias Unclear risk Unblinded study with alternation rather
than randomisation.
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Citron 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeon unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Multiple unblinded assessors throughout
study
Citron 2005
Methods Single-centre UK study
Randomised controlled trial
Recruitment between February 1998 and August 2002
Participants 100 participants
63 male:16 female (21 incomplete)
Mean age: 65 (SD 10) years
Inclusion criteria: yes: Dupuytren’s disease in 1 ray only and any degree of resultant
contracture
Exclusion criteria: yes: bleeding diathesis, recurrent disease
Interventions Bruner incision closed with Y-V plasties
vs
Longitudinal incision closed with z-plasties
Outcomes • Recurrence (reappearance of palpable disease)
◦ No differences between groups
• Deformity: preoperative, postoperative
◦ No differences between groups
• Extension
◦ No differences between groups
◦ Outcomes measured “in a special review clinic mostly by a registrar who had
not operated” at 1 year and 2 years after healing
• Complications reported? yes
• Details: total complications not different between groups; algodystrophy not
different between groups; digital nerve injury not different between groups
Notes Length of follow-up: 2 years
Low-quality evidence, as high risk of performance bias, which may have influenced
outcomes and imprecision
No funding sources acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers in envelopes
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Allocation concealment (selection bias) Low risk Sealed sequentially numbered envelopes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition unlikely to be related to true out-
come
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeon unblinded; participant possibly
unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Independent observer, but unclear whether
blinded
Collis 2013
Methods Single-centre New Zealand study
Randomised controlled clinical trial
Study period: 2010 to 2011
Participants 56 participants
45 male:11 female
Mean age: 68 (SD 8) years in intervention group; 67 (SD 9) years in control group
Inclusion criteria: yes: “Patients of all ages and surgery types were included, provided
they attended their first postoperative hand therapy appointment within 14 days after
surgery”
Exclusion criteria: yes: “K-wiring of the proximal interphalangeal joint during surgery
or inability to comply with hand therapy”
Interventions Night extension orthosis plus standard hand therapy
vs
Hand therapy alone (apart from participants in this group who had a net loss of ≥ 20
degrees at the PIPJ and/or a net loss of≥ 30 degrees at theMCPJ of the operated fingers,
in which case a splint was given)
Outcomes • Total active extension
◦ No significant differences at 3 months for little/ring/middle fingers
• Total active flexion
◦ No significant differences at 3 months for little/ring/middle fingers
• Composite finger flexion
◦ No significant differences at 3 months for little/ring/middle fingers
• Grip strength
◦ No significant differences in mixed-effect model averaged across
postoperative visits
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• Hand function (DASH)
◦ No significant differences in mixed-effect model averaged across
postoperative visits
Notes Length of follow-up: 3 months
Low-quality evidence, as inadequate detail provided on study design and high risk of
performance bias and imprecision
Funding source: A grant was received through the Clinical Centre for Research and
Effective Practice (CCREP) Innovation Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Inadequate detail: “participant selecting a
tag from an envelope with group allocation
concealed”
Allocation concealment (selection bias) Unclear risk Inadequate detail: “participant selecting a
tag from an envelope with group allocation
concealed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition described: split between groups;
attrition unlikely to be related to true out-
come
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Inadequate details of randomisation in pa-
per
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Degreef 2014
Methods Single-centre Belgian study
Randomised controlled clinical trial
Study period not stated
Participants 30 participants
26 male:4 female
Mean age: 63.5 (SD 8) years
Inclusion criteria: Adult patients scheduled for subtotal fasciectomy to treat Dupuytren’s
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Degreef 2014 (Continued)
disease were eligible for inclusion if they had a D score > 4
Exclusion criteria: patients undergoing a reintervention for recurrent contractures; pa-
tients with a need for skin grafts or flaps; premenopausal women; patients using anti-
inflammatory drugs; patients with a history of malignancy; patients with a known allergy
to tamoxifen
Interventions Segmental fasciectomy with 80 mg oral tamoxifen daily for 6 weeks before surgery
continuing until 12 weeks after surgery
vs
Segmental fasciectomy with 80 mg oral placebo daily for 6 weeks before surgery contin-
uing until 12 weeks after surgery
Outcomes • Improvement in extension deficit by joint
◦ No differences at MCPJ at 3 months, 12 months or 24 months; significantly
greater differences for tamoxifen group at PIPJ at 3 months and 12 months; not
significantly different at 24 months
• Tubiana index
◦ Significantly greater differences in tamoxifen group at 3 months; not
significantly different at 12 months nor 24 months
• Satisfaction visual analogue scale
◦ Significantly higher in tamoxifen group at 3 months; no significant
differences at 12 months or 24 months
• Hand function (DASH)
• No significant differences at 12 months nor 24 months
Notes Length of follow-up: 24 months
Low-quality evidence, as inadequate details on study design and imprecision
Funding source: Belgian Orthopaedic Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Inadequate detail: not described
Allocation concealment (selection bias) Unclear risk Inadequate detail: boxes used to store allo-
cation, but opacity not described; second
copies of allocations stored in envelopes
with inadequate details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition described; systematic differences
between groups unlikely
Selective reporting (reporting bias) Unclear risk No data presented for hand function
(DASH) at 3 months
Other bias Low risk Blinded study; hence blocked randomisa-
tion not problematic
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded outcome measurements
Howard 2009
Methods Single-centre UK study
Randomised controlled trial
Recruitment dates not specified
Participants 62 participants
Gender ratio not presented
Age data not presented
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions Absorbable polyglactin suture closure
vs
Non-absorbable polypropylene suture closure
Outcomes • Time spent managing wound at first postop visit
◦ Less time spent in wound management for absorbable group once outliers
excluded (P value = 0.003) (measured by the nurse reviewing the wound)
• Pain VAS at first postop visit (patient-reported)
• No difference between groups
• Complications described?: yes
• Details: group A - 1 × delayed wound healing, 1 × swollen hand; group B - 1 ×
wound infection, 2 × delayed healing, 2 × retained suture material
Notes Length of follow-up: primary outcome assessed at 10 to 14 days
Low-quality evidence, as reviewgroupwas concerned that exclusion of outliers despite use
of non-parametric statistics in analysis of primary outcome created significant differences
and imprecision
No funding sources acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Unclear risk Unclear from paper
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 of 62 missing
Selective reporting (reporting bias) High risk Protocol for exclusion of outliers not given;
non-parametric statistics used after test of
normality described; unclear why outliers
excluded; outlier exclusion may have influ-
enced outcome of study
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded until start of procedure
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessor unblinded
Jerosch-Herold 2011
Methods Multi-centre (5-centre) UK study
Randomised controlled trial
Recruitment between October 2007 and January 2009
Participants 154 participants
120 male:34 female
Mean age: 67.2 years in splint group; 67.5 years in no splint group
Inclusion criteria: yes: Patients withDupuytren’s disease affecting≥ 1 digit of either hand
and requiring fasciectomy or dermofasciectomy were invited to participate. Patients had
to be over 18 years of age and competent to give fully informed written consent
Exclusion criteria: yes: contracture of the thumb or first webspace
Interventions Static splint for 3 months postop
vs
No splint (apart from participants in this group who had a net loss ≥ 15 degrees at the
PIPJ and/or a net loss ≥ 20 degrees at the MCPJ of the operated fingers, in which case
a splint was given)
Outcomes • DASH PROM: 3 months, 6 months, 12 months
◦ No differences between groups
• Total active extension: 3 months, 6 months, 12 months
◦ No differences between groups
• Total active flexion: 3 months, 6 months, 12 months
◦ No differences between groups
• Patient satisfaction: 3 months, 6 months, 12 months
◦ No differences between groups
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Jerosch-Herold 2011 (Continued)
◦ DASH reported by participants; other measurements performed by 2 trained
research associates
• Complications described? no
Notes Length of follow-up: 12 months
Low-quality evidence due to risk of bias and imprecision
Funded by Action Medical Research Charity; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process at central site not
explained
Allocation concealment (selection bias) Low risk Central telephone cluster randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition recorded and explained
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Cluster randomisation used in an un-
blinded study, but unclear it if would have
introduced bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Patient-reported outcome measure un-
blinded but unclear whether likely to be bi-
ased; independent observermeasured range
of motion but unclear whether blinded
Kemler 2012
Methods 2-Centre Dutch study
Randomised controlled clinical trial
Recruitment between 2007 and 2008
Participants 54 participants
46 male:8 female
Mean age: 63 (SD 9) years in intervention group; 64 (SD 11) years in control group
Inclusion criteria: yes: “DD (Dupuytren’s disease) and a proximal inter-phalangeal (PIP)
joint flexion contracture of at least 30°”
Exclusion criteria: yes: “below 18 years of age, had undergone partial amputation or
arthrodesis of a digit or were patients with insufficient knowledge of theDutch language”
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Interventions 3-Month splinting protocol together with hand therapy
vs
Hand therapy alone
Outcomes • Extension deficit at PIPJ
◦ No significant differences
• Participant perceived change
◦ No significant differences
• Pain (numerical visual analogue scale)
◦ No significant differences
• Haematoma
◦ No significant differences
• Residual flexion deficit
◦ No significant differences
Notes Length of follow-up: 1 year
Low-quality evidence due to risk of bias and imprecision
No specific funding sources declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Not specified; allocation concealed from
outcome assessor but allocation conceal-
ment not clear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeon blinded but therapist and partici-
pant not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk All assessments by “same independent third
party, a resident who had no part in the
operative procedure or postoperative treat-
ment”, although blinding status not speci-
fied
53Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McMillan 2012
Methods Single-centre Canadian study
Randomised controlled trial
Recruitment dates not specified
Participants 47 participants
41 male:6 female
Mean age: 61.2 years
Inclusion criteria: yes: “at least one joint contracture of at least 20°”
Exclusion criteria: yes: “diabetes mellitus and those who had previously had hand surgery,
including PNA, on the affected hand for any reason”
Interventions Steroid injection at end of percutaneous needle fasciotomy, repeated at 6 weeks and 3
months, vs no steroid injection
Outcomes • Change and % change in total active extension deficit, described per joint: 6
weeks, 3 months, 6 months
• Significantly greater % improvement in TAED for all joints at at all time points,
and for MCPJs and PIPJs at 6 months, for steroid group (unclear who performed
outcome measurements)
• Complications described? yes
• Details: no infections; reported alterations in sensation or other side effects or
complications
Notes Length of follow-up: 6 months
Low-quality evidence due to risk of bias and imprecision
Funded by the Canadian Society of Plastic Surgeons; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Electronic random number generator
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions after randomisation
Selective reporting (reporting bias) Low risk Outcomes reported
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding; no sham injection for control
group
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Ullah 2009
Methods Single-centre UK study
Randomised controlled trial
Recruitment dates not specified
Participants 79 participants
65 male:14 female
Mean age: 62.9 (range 27 to 85) years
Inclusion criteria: yes: “primary Dupuytren’s contracture greater than 30° of the PIP
joint of a finger”
Exclusion criteria: yes: “receiving anticoagulation treatment or were unable to complete
questionnaires, give consent or attend for follow-up”
Interventions Firebreak full-thickness skin graft closure
vs
z-plasty closure
Outcomes • Degree of contracture: preoperative, 2 weeks, 3 months, 6 months, 12 months, 24
months, 36 months
◦ No differences in recurrence between groups
• Time to recurrence
◦ No differences between groups
• Range of motion
◦ No statistical analysis presented
• Time for surgery
◦ Significantly longer for skin graft group (P value = 0.01)
• Grip strength
◦ No differences between groups
• PEM PROM
◦ No statistical analysis presented
◦ Outcome measurements performed by a single surgeon; PEM reported by
participants
• Complications described? yes
• Details: infection, wound necrosis, wound dehiscence, altered sensation,
algodystrophy, haematoma
Notes Length of follow-up: 36 months
Low-quality evidence due to risk of bias and imprecision
No sources of funding acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation via sequential envelopes
Allocation concealment (selection bias) Unclear risk Sealed sequential envelopes but unclear
whether opaque
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not described
Selective reporting (reporting bias) Unclear risk 2-Week postoperative data not presented;
some data presented only graphically
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Randomisation not performed until after
contracture excised
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Independent observer unlikely to be
blinded
van Rijssen 2006
Methods Single-centre Dutch study
Randomised controlled trial
Recruitment between August 2002 and January 2005
Participants 125 hands in 121 participants
94 male:19 female; 8 incomplete
Mean age: 63 years
Inclusion criteria: yes: “(1) a flexion contracture of at least 30° in the MCP, PIP, or DIP
joints; (2) a clearly defined pathologic cord in the palmar fascia; and (3) willingness to
participate in this trial”
Exclusion criteria: yes: “(1) patients with postsurgical recurrence or extension of the
disease, (2) patients whowere not allowed to stop taking their anticoagulants, (3) patients
generally unfit to have surgery, and (4) patients who were not willing to participate in
this study or had a specific treatment wish”
Interventions Percutaneous needle fasciotomy
vs
Limited fasciectomy
Outcomes • Total passive extension deficit at MCPJ, PIPJ and DIPJ (presented as % change
and converted in Tubiana stage): preoperative, 1 week, 6 weeks
◦ No differences between procedures for Tubiana I and II contractures by 6
weeks; fasciectomy superior for Tubiana III and IV contractures by 6 weeks
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van Rijssen 2006 (Continued)
• Flexion deficit (distal palmar crease - fingertip pulp): preoperative, 1 week, 6 weeks
◦ Data described but no comparative statistical analysis presented
• DASH PROM: preoperative, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks
◦ No significant differences between procedures before surgery; significantly
lower DASH scores for needle fasciotomy at all time points after surgery
• Patient satisfaction: 6 weeks
◦ Angles measured by the surgeon; DASH and satisfaction reported by
participants
◦ Significantly better after needle fasciotomy
• Complications described? yes
• Details: infection, haematoma, wound slough, skin fissure, sympathetic dystrophy,
paraesthesia (defined as subjective tingling sensation without objective evidence of
altered sensation), altered sensation, digital nerve injury, tendon injury, revision surgery
Notes Length of follow-up: 6 weeks
Low-quality evidence due to risk of bias and imprecision
No sources of funding acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation via sealed sequential en-
velopes
Allocation concealment (selection bias) Unclear risk Sealed sequential envelopes but unclear
whether opaque
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not different between
groups
Selective reporting (reporting bias) Low risk All data reported
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
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van Rijssen 2012a
Methods (as per van Rijssen 2006)
Single-centre Dutch study
Randomised controlled trial
Recruitment between August 2002 and January 2005
Participants 93 participants (out of 113 patients studied in van Rijssen 2006)
76 male:17 female
Mean age 62.8 years for needle fasciotomy; 63.1 years for limited fasciectomy
Inclusion criteria: yes: “(1) a flexion contracture of at least 30° in the MCP, PIP, or DIP
joints; (2) a clearly defined pathologic cord in the palmar fascia; and (3) willingness to
participate in this trial”
Exclusion criteria: yes: “(1) patients with postsurgical recurrence or extension of the
disease, (2) patients whowere not allowed to stop taking their anticoagulants, (3) patients
generally unfit to have surgery, and (4) patients who were not willing to participate in
this study or had a specific treatment wish”
Interventions Percutaneous needle fasciotomy
vs
Limited fasciectomy
Outcomes • Recurrence (defined as recurrent deformity of 20 degrees in a joint initially
corrected to 0 to 5 degrees)
◦ Significantly higher recurrence after needle fasciotomy by 5 years (P value <
0.001)
• Passive extension deficit (per joint)
◦ No comparative analysis presented
• Patient satisfaction
◦ Significantly higher after fasciectomy (P value < 0.001)
• Likelihood of selecting treatment again
◦ Significantly higher after fasciectomy (P value = 0.008)
◦ Satisfaction and likelihood of selecting again were patient reported; unclear
who performed other measurements
• Complications described? no: described previously in van Rijssen 2006
Notes Length of follow-up: 5 years
Low-quality evidence due to risk of bias and imprecision
No sources of funding acknowledged; no conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes
Allocation concealment (selection bias) Unclear risk Unclear whether envelopes were numbered
but were numbered in van Rijssen 2006, in
which early outcomes of same study were
reported; unclear whether opaque
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Incomplete outcome data (attrition bias)
All outcomes
High risk Significantly different attrition between co-
horts possibly because of differences in true
outcomes
Selective reporting (reporting bias) Low risk All outcomes presented
Other bias Low risk Noblocked randomisation in anunblinded
study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Abbreviations:
5-FU: 5-Fluorouracil.
DASH: Disabilities of the Arm, Shoulder and Hand Scale.
DIPJ: Distal interphalangeal joint.
MCPJ: Metacarpophalangeal joint.
PIPJ: Proximal interphalangeal joint.
PROM: Patient-reported outcome measure.
TAED: Total active extension deficit.
VAS: Visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Atroshi 2014 Excluded on the basis of question 5 of Appendix 3; not a randomised or pseudorandomised trial
Barros 1997 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Bendon 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Braga Silva 1999 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Braga Silva 2002 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
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Castro 1981 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Cervero 2013 Excluded on the basis of question 5 of Appendix 3; not a randomised or pseudorandomised trial
Craft 2011 Excluded on the basis of question 5 of Appendix 3; no concurrent control and intervention groups
Dias 2013 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Dib 2008 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Dickie 1967 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Erne 2014 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Evans 2002 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Ferry 2013 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Galbiatti 1995 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Glassey 2001 Excluded on the basis of question 5 of Appendix 3; retrospective service evaluation of participants treated
with a splint and those treated without a splint based on clinical grounds rather than randomisation/pseudo-
randomisation
Gomes 1984 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Halliday 1966 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Herrera 2013 Excluded on the basis of question 5 of Appendix 3; not a randomised or pseudorandomised trial
Hovius 2011 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Jerosch-Herold 2008 Excluded on the basis of question 3 of Appendix 3; publication reports the protocol of a study; final study is
described in Jerosch-Herold 2011, which is among the Included studies
60Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Larson 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Malta 1984 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Malta 2013 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Moraes Neto 1996 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Nancoo 2007 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Nydick 2013 Excluded on the basis of question 5 of Appendix 3; not a randomised or pseudorandomised trial
Orbezo 1999 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Ould-Slimane 2013 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Pereira 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Pesco 2008 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Pess 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Reuben 2006 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Rives 1992 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Skoff 2004 Excluded on the basis of question 5 of Appendix 3; no concurrent control and intervention groups
van Rijssen 2012b Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Vollbach 2013 Excluded on the basis of question 5 of Appendix 3; not a randomised or pseudorandomised trial
von Campe 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
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White 2012 Excluded on the basis of question 4 of Appendix 3; no comparison of an intervention vs control and no
comparison of 2 interventions
Characteristics of studies awaiting assessment [ordered by study ID]
Gazdzik 1997
Methods Unclear
Participants
Interventions
Outcomes
Notes
Hazarika 1979
Methods Single-centre UK study
Unclear study design
Recruitment dates not specified
Participants 39 participants
17 male:4 female; 18 incomplete
Mean age: not presented, range 46 to 76 years
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions Intermittent pneumatic postoperative compression
vs
Boxing glove dressing and roller towel elevation
Outcomes • Hand volume: preoperative, postoperative (unclear when), differences
◦ Significantly less swelling for pneumatic compression group (P value < 0.001)
• Wound discharge/dressing saturation
◦ No statistical analysis
• Pain and analgesia use
◦ No statistical analysis
• Haematoma formation
◦ No statistical analysis
◦ Outcome measurements performed during “at least one follow-up appointment”, and from
physiotherapy notes; unclear who performed measurements
• Complications reported? yes
• Details: haematoma formation as above; “no infections”
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Notes Length of follow-up: 7 days - “one follow-up appointment”
Low-quality evidence, as extremely limited details of study design provided
Funded by the Department of Health and Social Security; no conflicts of interest declared
Slullitel 1987
Methods Unclear
Participants
Interventions
Outcomes
Notes
Ward 1976
Methods Single-centre UK study
Unclear study design
Recruitment dates not specified
Participants 20 participants
13 male:7 female
Mean age: not reported (range 42 to 81 years)
Inclusion criteria: yes: “previously untreated simple Dupuytren’s disease”
Exclusion criteria: yes: “any illness or medication that might influence fluid retention”
Interventions Elevated hand table for surgery
vs
Intraoperative tourniquet
Outcomes • Ratio of 28-day postop hand volume:preop hand volume
◦ Ratio significantly lower with elevated hand table than with tourniquet (P value < 0.001)
◦ Unclear who performed outcome measurements
• Complications described? yes
• Details: 1 infected hand excluded; otherwise described as “no complications”
Notes Length of follow-up: 28 days
Low-quality evidence
No funding sources acknowledged; no conflicts of interest declared
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Yoshida 1998
Methods Unclear
Participants
Interventions
Outcomes
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Preoperative measurements
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH 2 210 Mean Difference (IV, Random, 95% CI) 1.00 [-2.74, 4.74]
2 Total active extension 2 240 Mean Difference (IV, Random, 95% CI) -1.89 [-7.72, 3.94]
2.1 Middle finger 1 13 Mean Difference (IV, Random, 95% CI) -12.0 [-33.20, 9.20]
2.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) 9.0 [-21.50, 39.50]
2.3 Little finger 1 51 Mean Difference (IV, Random, 95% CI) -12.0 [-32.31, 8.31]
2.4 No subgroup by digit 1 154 Mean Difference (IV, Random, 95% CI) -0.40 [-6.90, 6.10]
3 Total active flexion 2 232 Mean Difference (IV, Random, 95% CI) 2.42 [-4.98, 9.83]
3.1 Middle finger 1 13 Mean Difference (IV, Random, 95% CI) 6.0 [-11.52, 23.52]
3.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) 11.00 [-0.47, 22.47]
3.3 Little finger 1 43 Mean Difference (IV, Random, 95% CI) -9.0 [-21.26, 3.26]
3.4 No subgroup by digit 1 154 Mean Difference (IV, Random, 95% CI) 2.40 [-3.35, 8.15]
Comparison 2. Effects of 3 months of postoperative night splinting (intention-to-treat)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH score at 3 months 2 205 Mean Difference (IV, Random, 95% CI) 1.15 [-2.32, 4.62]
2 Total active extension at 3
months
2 225 Mean Difference (IV, Random, 95% CI) -2.21 [-8.01, 3.59]
2.1 Middle finger 1 12 Mean Difference (IV, Random, 95% CI) 4.0 [-30.26, 38.26]
2.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) -4.0 [-23.24, 15.24]
2.3 Little finger 1 40 Mean Difference (IV, Random, 95% CI) -5.0 [-27.35, 17.35]
2.4 No subgroup by digit 1 151 Mean Difference (IV, Random, 95% CI) -2.0 [-8.43, 4.43]
3 Total active flexion at 3 months 2 225 Mean Difference (IV, Random, 95% CI) 12.36 [1.21, 23.50]
3.1 Middle finger 1 12 Mean Difference (IV, Random, 95% CI) 29.00 [3.96, 54.04]
3.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) 24.0 [0.21, 47.79]
3.3 Little finger 1 40 Mean Difference (IV, Random, 95% CI) 9.0 [-9.12, 27.12]
3.4 No subgroup by digit 1 151 Mean Difference (IV, Random, 95% CI) 4.60 [-3.25, 12.45]
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Comparison 3. Effects of 3 months of postoperative night splinting (per-protocol)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH score at 3 months 2 184 Mean Difference (IV, Random, 95% CI) 1.01 [-2.85, 4.86]
2 Total active extension at 3
months [degrees]
2 206 Mean Difference (IV, Random, 95% CI) -9.50 [-21.14, 2.15]
2.1 Middle finger 1 12 Mean Difference (IV, Random, 95% CI) 3.90 [-29.81, 37.61]
2.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) -16.9 [-33.79, -0.01]
2.3 Little finger 1 39 Mean Difference (IV, Random, 95% CI) -22.20 [-41.05, -3.
35]
2.4 No subgroup by digit 1 133 Mean Difference (IV, Random, 95% CI) -1.90 [-8.77, 4.97]
3 Total active flexion at 3 months
[degrees]
2 206 Mean Difference (IV, Random, 95% CI) 12.64 [3.68, 21.60]
3.1 Middle finger 1 12 Mean Difference (IV, Random, 95% CI) 28.60 [3.79, 53.41]
3.2 Ring finger 1 22 Mean Difference (IV, Random, 95% CI) 21.70 [-0.80, 44.20]
3.3 Little finger 1 39 Mean Difference (IV, Random, 95% CI) 13.10 [-4.61, 30.81]
3.4 No subgroup by digit 1 133 Mean Difference (IV, Random, 95% CI) 6.80 [-1.42, 15.02]
Analysis 1.1. Comparison 1 Preoperative measurements, Outcome 1 DASH.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 1 Preoperative measurements
Outcome: 1 DASH
Study or subgroup Splint No Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Collis 2013 26 14 (12) 30 13 (14) 30.2 % 1.00 [ -5.81, 7.81 ]
Jerosch-Herold 2011 77 16.4 (15.1) 77 15.4 (13.2) 69.8 % 1.00 [ -3.48, 5.48 ]
Total (95% CI) 103 107 100.0 % 1.00 [ -2.74, 4.74 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Preoperative measurements, Outcome 2 Total active extension.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 1 Preoperative measurements
Outcome: 2 Total active extension
Study or subgroup Splint No Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 8 59 (24) 5 71 (15) 7.6 % -12.00 [ -33.20, 9.20 ]
Subtotal (95% CI) 8 5 7.6 % -12.00 [ -33.20, 9.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 Ring finger
Collis 2013 11 73 (42) 11 64 (30) 3.7 % 9.00 [ -21.50, 39.50 ]
Subtotal (95% CI) 11 11 3.7 % 9.00 [ -21.50, 39.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 Little finger
Collis 2013 21 80 (30) 30 92 (44) 8.2 % -12.00 [ -32.31, 8.31 ]
Subtotal (95% CI) 21 30 8.2 % -12.00 [ -32.31, 8.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
4 No subgroup by digit
Jerosch-Herold 2011 77 50.7 (22.2) 77 51.1 (18.8) 80.5 % -0.40 [ -6.90, 6.10 ]
Subtotal (95% CI) 77 77 80.5 % -0.40 [ -6.90, 6.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 117 123 100.0 % -1.89 [ -7.72, 3.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.53)
Test for subgroup differences: Chi2 = 2.52, df = 3 (P = 0.47), I2 =0.0%
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Analysis 1.3. Comparison 1 Preoperative measurements, Outcome 3 Total active flexion.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 1 Preoperative measurements
Outcome: 3 Total active flexion
Study or subgroup No Splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 5 248 (18) 8 242 (11) 13.5 % 6.00 [ -11.52, 23.52 ]
Subtotal (95% CI) 5 8 13.5 % 6.00 [ -11.52, 23.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Ring finger
Collis 2013 11 241 (16) 11 230 (11) 23.6 % 11.00 [ -0.47, 22.47 ]
Subtotal (95% CI) 11 11 23.6 % 11.00 [ -0.47, 22.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
3 Little finger
Collis 2013 22 233 (25) 21 242 (15) 21.9 % -9.00 [ -21.26, 3.26 ]
Subtotal (95% CI) 22 21 21.9 % -9.00 [ -21.26, 3.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
4 No subgroup by digit
Jerosch-Herold 2011 77 226.2 (15) 77 223.8 (20.9) 41.1 % 2.40 [ -3.35, 8.15 ]
Subtotal (95% CI) 77 77 41.1 % 2.40 [ -3.35, 8.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 115 117 100.0 % 2.42 [ -4.98, 9.83 ]
Heterogeneity: Tau2 = 26.20; Chi2 = 5.64, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 5.64, df = 3 (P = 0.13), I2 =47%
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Analysis 2.1. Comparison 2 Effects of 3 months of postoperative night splinting (intention-to-treat),
Outcome 1 DASH score at 3 months.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-treat)
Outcome: 1 DASH score at 3 months
Study or subgroup No Splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Collis 2013 29 11 (16) 24 10 (9) 25.7 % 1.00 [ -5.85, 7.85 ]
Jerosch-Herold 2011 76 10.8 (12.5) 76 9.6 (12.8) 74.3 % 1.20 [ -2.82, 5.22 ]
Total (95% CI) 105 100 100.0 % 1.15 [ -2.32, 4.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Effects of 3 months of postoperative night splinting (intention-to-treat),
Outcome 2 Total active extension at 3 months.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-treat)
Outcome: 2 Total active extension at 3 months
Study or subgroup No Splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD)[degrees]N Mean(SD)[degrees] IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 5 30 (36) 7 26 (18) 2.9 % 4.00 [ -30.26, 38.26 ]
Subtotal (95% CI) 5 7 2.9 % 4.00 [ -30.26, 38.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Ring finger
Collis 2013 11 24 (24) 11 28 (22) 9.1 % -4.00 [ -23.24, 15.24 ]
Subtotal (95% CI) 11 11 9.1 % -4.00 [ -23.24, 15.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 Little finger
Collis 2013 20 33 (34) 20 38 (38) 6.7 % -5.00 [ -27.35, 17.35 ]
Subtotal (95% CI) 20 20 6.7 % -5.00 [ -27.35, 17.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 No subgroup by digit
Jerosch-Herold 2011 76 30.9 (20.7) 75 32.9 (19.6) 81.3 % -2.00 [ -8.43, 4.43 ]
Subtotal (95% CI) 76 75 81.3 % -2.00 [ -8.43, 4.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 112 113 100.0 % -2.21 [ -8.01, 3.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Chi2 = 0.22, df = 3 (P = 0.97), I2 =0.0%
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Analysis 2.3. Comparison 2 Effects of 3 months of postoperative night splinting (intention-to-treat),
Outcome 3 Total active flexion at 3 months.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 2 Effects of 3 months of postoperative night splinting (intention-to-treat)
Outcome: 3 Total active flexion at 3 months
Study or subgroup No Splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD)[degrees]N Mean(SD)[degrees] IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 5 245 (16) 7 216 (28) 14.9 % 29.00 [ 3.96, 54.04 ]
Subtotal (95% CI) 5 7 14.9 % 29.00 [ 3.96, 54.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 Ring finger
Collis 2013 11 232 (18) 11 208 (36) 16.0 % 24.00 [ 0.21, 47.79 ]
Subtotal (95% CI) 11 11 16.0 % 24.00 [ 0.21, 47.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
3 Little finger
Collis 2013 20 229 (22) 20 220 (35) 23.1 % 9.00 [ -9.12, 27.12 ]
Subtotal (95% CI) 20 20 23.1 % 9.00 [ -9.12, 27.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
4 No subgroup by digit
Jerosch-Herold 2011 76 217.6 (22.5) 75 213 (26.5) 46.0 % 4.60 [ -3.25, 12.45 ]
Subtotal (95% CI) 76 75 46.0 % 4.60 [ -3.25, 12.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 112 113 100.0 % 12.36 [ 1.21, 23.50 ]
Heterogeneity: Tau2 = 54.30; Chi2 = 5.16, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 5.16, df = 3 (P = 0.16), I2 =42%
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Analysis 3.1. Comparison 3 Effects of 3 months of postoperative night splinting (per-protocol), Outcome 1
DASH score at 3 months.
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 3 Effects of 3 months of postoperative night splinting (per-protocol)
Outcome: 1 DASH score at 3 months
Study or subgroup No splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Collis 2013 24 11 (16.5) 27 9.7 (9) 26.9 % 1.30 [ -6.12, 8.72 ]
Jerosch-Herold 2011 68 10.7 (13) 65 9.8 (13.5) 73.1 % 0.90 [ -3.61, 5.41 ]
Total (95% CI) 92 92 100.0 % 1.01 [ -2.85, 4.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Effects of 3 months of postoperative night splinting (per-protocol), Outcome 2
Total active extension at 3 months [degrees].
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 3 Effects of 3 months of postoperative night splinting (per-protocol)
Outcome: 2 Total active extension at 3 months [degrees]
Study or subgroup No splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 5 29.6 (35.5) 7 25.7 (17.5) 9.7 % 3.90 [ -29.81, 37.61 ]
Subtotal (95% CI) 5 7 9.7 % 3.90 [ -29.81, 37.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Ring finger
Collis 2013 9 15.9 (16.1) 13 32.8 (24.3) 24.7 % -16.90 [ -33.79, -0.01 ]
Subtotal (95% CI) 9 13 24.7 % -16.90 [ -33.79, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
3 Little finger
Collis 2013 16 21.4 (15.7) 23 43.6 (42.1) 21.9 % -22.20 [ -41.05, -3.35 ]
Subtotal (95% CI) 16 23 21.9 % -22.20 [ -41.05, -3.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
4 No subgroup by digit
Jerosch-Herold 2011 68 31.1 (21) 65 33 (19.4) 43.7 % -1.90 [ -8.77, 4.97 ]
Subtotal (95% CI) 68 65 43.7 % -1.90 [ -8.77, 4.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 98 108 100.0 % -9.50 [ -21.14, 2.15 ]
Heterogeneity: Tau2 = 68.62; Chi2 = 6.12, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Chi2 = 6.12, df = 3 (P = 0.11), I2 =51%
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Analysis 3.3. Comparison 3 Effects of 3 months of postoperative night splinting (per-protocol), Outcome 3
Total active flexion at 3 months [degrees].
Review: Surgery for Dupuytren’s contracture of the fingers
Comparison: 3 Effects of 3 months of postoperative night splinting (per-protocol)
Outcome: 3 Total active flexion at 3 months [degrees]
Study or subgroup No splint Splint
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Middle finger
Collis 2013 5 245 (15.9) 7 216.4 (27.7) 11.5 % 28.60 [ 3.79, 53.41 ]
Subtotal (95% CI) 5 7 11.5 % 28.60 [ 3.79, 53.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
2 Ring finger
Collis 2013 9 232.9 (20) 13 211.2 (33.7) 13.7 % 21.70 [ -0.80, 44.20 ]
Subtotal (95% CI) 9 13 13.7 % 21.70 [ -0.80, 44.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
3 Little finger
Collis 2013 16 231.4 (22.3) 23 218.3 (34.1) 20.4 % 13.10 [ -4.61, 30.81 ]
Subtotal (95% CI) 16 23 20.4 % 13.10 [ -4.61, 30.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
4 No subgroup by digit
Jerosch-Herold 2011 68 218.7 (21.5) 65 211.9 (26.5) 54.4 % 6.80 [ -1.42, 15.02 ]
Subtotal (95% CI) 68 65 54.4 % 6.80 [ -1.42, 15.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 98 108 100.0 % 12.64 [ 3.68, 21.60 ]
Heterogeneity: Tau2 = 20.81; Chi2 = 3.85, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Chi2 = 3.85, df = 3 (P = 0.28), I2 =22%
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A D D I T I O N A L T A B L E S
Table 1. Outcomes measured and length of study follow-up
Article Aspect
of care
studied
Length
of fol-
low-up,
months
Out-
comes
mea-
sured
Recur-
rence
Exten-
sion
deficit
Flexion
deficit
Total
motion
PROM Time Compli-
cations
as an out-
come
measure
Hand vol-
ume
Other
Bhatia
2002
Tech-
nical re-
fine-
ment
0.5 - - - - + + - - Wound
appear-
ance
Bul-
strode
2004
Tech-
nical re-
fine-
ment
18 - + - + - + - - -
Chignon-
Sicard
2012
Rehabil-
itation
adjunct
2 - - - - - + + - -
Citron
2003
Tech-
nical re-
fine-
ment
24 + - + - - - - - -
Citron
2005
Tech-
nical re-
fine-
ment
24 + + - - - - - - -
Collis
2013
Rehabil-
itation
adjunct
3 - + + - + - - - Grip
strength,
compos-
ite flexion
Degreef
2014
Tech-
nical re-
fine-
ment
24 + + - - + - + - -
Howard
2009
Tech-
nical re-
0.5 - - - - + + - - -
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Table 1. Outcomes measured and length of study follow-up (Continued)
fine-
ment
Jerosch-
Herold
2011
Rehabil-
itation
adjunct
12 - + + + + - - - -
Kemler
2012
Rehabil-
itation
adjunct
12 - + - - + - + - -
McMil-
lan
2012
Tech-
nical re-
fine-
ment
6 - + - - - - - - -
Ullah
2009
Proce-
dure
type
36 + + - + + + - - Grip
strength
van
Rijssen
2006
Proce-
dure
type
1.5 - + + - + - + - -
van
Rijssen
2012a
Proce-
dure
type
60 + + - - + - - - -
Table 2. Six-week outcomes described in van Rijssen 2006
Tubiana stage preop % improvement in TPED for nee-
dle fasciotomy
% improvement in TPED for fa-
sciectomy
Significance of differences between
procedures
I 71 82 0.329
II 67 78 0.071
III 46 75 0.000
IV 47 79 0.004
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Dupuytren Contracture] explode all trees 36
#2 MeSH descriptor: [Fibroma] explode all trees 4
#3 Dupuytren*:ti,ab,kw (Word variations have been searched) 49
#4 Fibromatosis 12
#5 MeSH descriptor: [Fascia] explode all trees 142
#6 palmar fibromatosis 1
#7 viking disease 1
#8 palmar fascia 7
#9 MeSH descriptor: [Fibroblasts] explode all trees 161
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 357
Appendix 2. MEDLINE search strategy: Ovid (numbers of results from original search in 2012)
Database:OvidMEDLINE(R) In-Process&OtherNon-IndexedCitations andOvidMEDLINE(R) <1948 to Present>Search Strategy:
--------------------------------------------------------------------------------
1 exp Dupuytren Contracture/ (2121)
2 exp Fibroma/ (11134)
3 Fibromatosis.tw. (2482)
4 exp Fascia/ (7945)
5 Fibroblasts/ (93904)
6 (palmar adj3 fascia).tw. (212)
7 Dupuytren*.tw. (2087)
8 (palmar adj3 fibromatosis).tw. (65)
9 (viking adj3 disease).tw. (1)
10 or/1-9 (115275)
11 randomized controlled trial.pt. (336898)
12 controlled clinical trial.pt. (85168)
13 randomized.ab. (252166)
14 placebo.ab. (139534)
15 clinical trials as topic.sh. (162410)
16 randomly.ab. (184567)
17 trial.ti. (108505)
18 or/11-17 (807835)
19 exp animals/ not humans.sh. (3780560)
20 18 not 19 (746667)
21 10 and 20 (767)
Appendix 3. EMBASE search strategy
EMBASE Classic+EMBASE <1947 to 2012 September 17>
--------------------------------------------------------------------------------
1 Dupuytren contracture/ (3303)
2 fibroma/ (12928)
3 Fibromatosis.tw. (3239)
4 fascia/ (9898)
5 *fibroblast/ (30576)
6 (palmar adj3 fascia).tw. (309)
7 Dupuytren*.tw. (3062)
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8 (palmar adj3 fibromatosis).tw. (84)
9 (viking adj3 disease).tw. (1)
10 or/1-9 (59116)
11 random$.tw. (776280)
12 factorial$.tw. (20394)
13 crossover$.tw. (45803)
14 cross over.tw. (20874)
15 cross-over.tw. (20874)
16 placebo$.tw. (189116)
17 (doubl$ adj blind$).tw. (140770)
18 (singl$ adj blind$).tw. (12915)
19 assign$.tw. (216631)
20 allocat$.tw. (72946)
21 volunteer$.tw. (171262)
22 crossover procedure/ (35355)
23 double blind procedure/ (115561)
24 randomized controlled trial/ (331643)
25 single blind procedure/ (16422)
26 or/11-25 (1294294)
27 10 and 26 (1139)
Appendix 4. CINAHL search strategy
CINAHL via Ebscohost - 1985-2012
S18 S5 and S17
S17 S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16
S16 TX allocat* random*
S15 (MH “Quantitative Studies”)
S14 (MH “Placebos”)
S13 TX placebo*
S12 TX random* allocat*
S11 (MH “Random Assignment”)
S10 TX randomi* control* trial*
S9 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S8 TX clinic* n1 trial*
S7 PT Clinical trial
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(Continued)
S6 (MH “Clinical Trials+”)
S5 S1 or S2 or S3 or S4
S4 “Dupuytren”
S3 (MH “Fascia”)
S2 “Fibromatosis”
S1 (MM “Dupuytren’s Contracture”)
Appendix 5. LILACS search strategy
LILACS (Latin American and Caribbean Health Sciences) - 1982 to current date
Search terms: dupuytren’s contracture
Appendix 6. ProQuest Dissertations & Theses search strategy
ProQuest Dissertations & Theses (PQDT) (all years)
Set# Searched for Databases Results
S1 dupuytren’s contracture ProQuest Dissertations & Theses
(PQDT)
18
S2 Fibroma ProQuest Dissertations & Theses
(PQDT)
256
S3 Fibromatosis ProQuest Dissertations & Theses
(PQDT)
118
S4 palmar fibromatosis ProQuest Dissertations & Theses
(PQDT)
2
S6 palmar fascia ProQuest Dissertations & Theses
(PQDT)
86
S7 “viking disease” ProQuest Dissertations & Theses
(PQDT)
0
S8 ab(viking disease) ProQuest Dissertations & Theses
(PQDT)
1
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S9 S1 OR S2 OR S3 OR S4 OR S6 OR S7
OR S8
ProQuest Dissertations & Theses
(PQDT)
462
Appendix 7. ISI Web of Science search strategy
ISIWeb of Science via ThomsonWeb of Knowledge Conference Proceedings Citation Index - Science (CPCI-S) -- 1990-present
Topic=(dupuytren contracture)
Refined by: Web of Science Categories=(SURGERY ) AND Document Types=( PROCEEDINGS PAPER OR MEETING AB-
STRACT )
Databases=CPCI-S Timespan=All Years
Lemmatization=On
Appendix 8. Clinicaltrials.gov search strategy
(advanced search screen)
Conditions: Dupuytren’s contracture
Appendix 9. Study eligibility form
Study eligibility form - Surgery for Dupuytren’s disease
Authors
Title
Journal
Date of publication
Q1. Does the paper report the
outcome of a clinical study?
(i.e. not a review article or just
a paper describing an opera-
tive technique description)?
Yes
Next question
No
Exclude
Unclear
Refer
Q2. Participant
Have participants had a sur-
gical intervention for
Dupuytren’s contracture of a
finger?
Yes
Next question
No
Exclude
Unclear
Refer
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Q3. Outcomes
Did the study report short-
term or long-term outcomes
(recurrence) of surgery?
Yes
Next question
No
Exclude
Unclear
Refer
Q4. Intervention
Didparticipants receive an in-
tervention compared with a
control group, or were at least
2 interventions compared?
Yes
Next question
No
Exclude
Unclear
Refer
Q5. Type of study
Was the study randomised or
quasi-randomised?
Yes
Include
No
Exclude
Unclear
Refer
Appendix 10. Assessment of potential for bias in report (tool of The Cochrane Collaboration for
assessing risk of bias)
Paper title
Paper authors
Reviewer
Domain Support for judgement Review authors’ judgement
Selection bias Insert description, preferably a direct
quote from report or correspondence, and
add comment
One of : “Low risk”, “High risk”, “Un-
clear risk”
Random sequence generation Describe the method used to generate the
allocation sequence in sufficient detail to
allow an assessment of whether it should
produce comparable groups
Selection bias (biased allocation to inter-
ventions) due to inadequate generation of
a randomised sequence
Allocation concealment Describe the method used to conceal the
allocation sequence in sufficient detail to
determinewhether intervention allocations
could have been foreseen in advance of, or
during, enrolment
Selection bias (biased allocation to inter-
ventions) due to inadequate concealment
of allocations before assignment
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Performance bias
Blinding of participants and personnel
Assessments should be made for each main
outcome (or class of outcomes)
Describe all measures used, if any, to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received. Provide any information re-
lated to whether intended blinding was ef-
fective
Performance bias due to knowledge of al-
located interventions by participants and
personnel during the study
Detection bias
Blinding of outcome assessment Assess-
ments should be made for each main outcome
(or class of outcomes)
Describe all measures used, if any, to
blind outcome assessors fromknowledge of
which intervention a participant received.
Provide any information related to whether
intended blinding was effective
Detection bias due to knowledge of allo-
cated interventions by outcome assessors
Attrition bias
Incomplete outcome data Assessments
should be made for each main outcome (or
class of outcomes)
Describe completeness of outcome data
for each main outcome, including attrition
and exclusions from analysis. State whether
attrition and exclusions were reported,
numbers in each intervention group (com-
pared with total randomised participants)
, reasons for attrition/exclusions when re-
ported and any re-inclusions in analyses
performed by review authors
Attrition bias due to amount, nature or
handling of incomplete outcome data
Reporting bias
Selective reporting State how the possibility of selective out-
come reportingwas examined by the review
authors, and what they found
Reporting bias due to selective outcome re-
porting
Other bias
Other sources of bias State any important concerns about bias
not addressed in other domains of the tool
If particular questions/entries were pre-
specified in the review protocol, responses
should be provided for each question/entry
Bias due to problems not covered elsewhere
in the table
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Appendix 11. Paper assessment form
Surgery for Dupuytren’s disease - Study checklist
Authors and year
Title
Journal/Source if
not published
Study ID
(Revman)
Date of extraction
Study design
Single/Multi-
centre
Study setting (country)
Number of par-
ticipants
Mean (SD:range) age
Male:Female
Inclusion criteria Exclusion criteria
Randomisation
technique • Random
num-
bers
• Quasi-
ran-
dom
• Not
stated
Concealment of allocation se-
quence?
Yes (envelopes, etc.)
No
Unclear
Blinding of par-
ticipant
Yes
No
Un-
clear
Incomplete outcome data
(%FU)
Yes
No
Unclear
Interventions
Intervention Control intervention
Length of fol-
low-up
(mean, SD, me-
dian, min, max)
Withdrawals (and why)
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Number lost to
follow-up
Outcomes assessed
Recurrence Recurrence No. Rec. Total
Treat-
ment
Con-
trol
treat-
ment
Pre-op contrac-
ture (mean/SD)
MCP PIP Combined
Imm post-op
contracture
MCP PIP Combined
Final
contracture
MCP PIP Combined
Complications
of surgery
Infection (definition)
Digital nerve injury
Tendon injury
Other
Other
outcomes
Quality of evi-
dence
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H I S T O R Y
Protocol first published: Issue 10, 2012
Review first published: Issue 12, 2015
Date Event Description
14 November 2008 Amended Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
Jeremy Rodrigues
Contributed to authoring of the protocol. Referenced the protocol. Contributed to the design of the search strategy. Screened abstracts.
Assessed risks of bias. Extracted data. Performed meta-analysis. Co-authored the main text. Read and approved the final version.
Giles Becker
Contributed to the design of the review. Contributed to the design of the statistical analysis. Screened abstracts. Read and approved
the final version.
Cathy Ball
Contributed to the design of the protocol. Contributed to the search strategy. Assessed risks of bias. Extracted data. Read and approved
the final version.
Weiya Zhang
Re-designed the methodology and statistics components of the protocol, following review. Read and approved the final version.
Henk Giele
Contributed to the design of the review. Tested different search strategies to compare effectiveness and appropriateness. Read and
approved the final version.
Jonathan Hobby
Contributed to the design of the protocol. In particular, contributed to the design of the statistical analysis. Read and approved the
final version.
Anna L. Pratt
Contributed to the interpretation of results, particularly of the meta-analysis. Read and approved the final version.
Tim Davis
Conceived of the review. Acted as guarantor of the review. Served as primary author of the protocol. Resolved conflicts in study selection,
risk of bias assessment and data extraction. Contributed to the authorship of the review. Read and approved the final version.
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D E C L A R A T I O N S O F I N T E R E S T
None to declare.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• British Society for Surgery of the Hand (BSSH), UK.
Contributed to funding Mr Rodrigues’ Research Fellowship
• Nottingham Hospitals Charity, UK.
Contributed to funding Mr Rodrigues’ Research Fellowship
• Nottingham Orthopaedic Walk, UK.
Contributed to funding Mr Rodrigues’ Research Fellowship
• National Institute for Health and Care Excellence (NICE) Fellows & Scholars Programme, UK.
A scholarship has provided analytical and educational support during Mr Rodrigues’ period of full-time research, and a fellowship has
provided further support since.
• Kennedy Institute Trust for Rheumatology Research and Health Innovation Challenge Fund (Wellcome Trust + Department of
Health), UK.
Contributed to funding Catherine Ball
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As the result of difficulty gaining access, the following resources were not searched.
• Cochrane Wounds Group Specialised Register BNI (British Nursing Index and Archive).
• Sciverse.
• Zetoc.
As the journals listed for handsearching are currently indexed in databases searched electronically, we deemed handsearching to be
redundant and we did not perform a handsearch.
Two additional resources were searched: ISI Web of Science was chosen as a source of conference abstracts, and clinicaltrials.gov was
searched.
Given the comprehensive and inclusive nature of the search strategies listed in Appendix 1 and Appendix 2, and the large number of
references retrieved (2464), we believe that this search was comprehensive.
The primary outcomes studied have been reordered to reflect the increasing importance of patient-reported outcomes among clinical
studies since the time the protocol was first written.
86Surgery for Dupuytren’s contracture of the fingers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
